



**ourofino**  
saúde animal

Tá bem  
cuidado

## Ourofino S.A. and Subsidiaries

**Condensed individual and consolidated interim financial statements for the quarter ended March 31, 2026, and report on the review of condensed interim financial statements.**

(A free translation of the original report in Portuguese containing financial information)





KPMG Auditores Independentes Ltda.  
Avenida Presidente Vargas, 2.121  
Salas 1401 a 1405, 1409 e 1410 - Jardim América  
Edifício Times Square Business  
14020-260 - Ribeirão Preto/SP - Brasil  
Caixa Postal 457 - CEP 14001-970 - Ribeirão Preto/SP - Brasil  
Telefone +55 (16) 3323-6650  
kpmg.com.br

## **Report on review of the individual and consolidated interim accounting information**

To the Shareholders, Board of Directors and Management of  
**Ourofino S.A.**  
Cravinhos – São Paulo

### ***Introduction***

We have reviewed the accompanying individual and consolidated interim financial statements of Ourofino S.A. (the “Company”), identified as Parent and Consolidated, respectively, included in the Interim Financial Information Form (ITR) for the quarter ended March 31, 2026, which comprises the individual and consolidated balance sheet as of March 31, 2026 and the related individual and consolidated statements of profit or loss, of comprehensive income (loss), of changes in equity and of cash flows for the three-month period then ended, including the explanatory notes.

The Executive Board is responsible for the preparation of the individual and consolidated interim financial statements in accordance with technical pronouncement CPC 21 (R1) - Interim Financial Reporting and international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - IASB, as well as for the presentation of these statements in accordance with the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of the Interim Financial Information (ITR). Our responsibility is to express a conclusion on these interim financial statements based on our review.

### ***Scope of review***

We conducted our review in accordance with Brazilian and International Standards on Review of Interim Financial Information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### ***Conclusion on the individual and consolidated interim financial statements***

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial statements included in the interim financial information referred to above were not prepared, in all material respects, in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34, applicable to the preparation of the ITR, and presented in accordance with the standards issued by the CVM.

***Other matters***

***Statements of value added***

The interim financial statements referred to above include the individual and consolidated statements of value added (DVA) for the three-month period ended March 31, 2026, prepared under the responsibility of the Company's Executive Board and disclosed as supplemental information for purposes of the international standard IAS 34. These statements have been subject to review procedures performed together with the ITR to reach a conclusion on whether they were reconciled with the individual and consolidated interim financial statements and accounting records, as applicable, and whether their form and content are in accordance with the criteria set out in technical pronouncement CPC 09 - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements of value added were not appropriately prepared, in all material respects, in relation to the criteria defined in this standard and consistently with the individual and consolidated interim financial statements taken as a whole.

Ribeirão Preto, May 05, de 2026

KPMG Auditores Independentes Ltda.  
CRC 2SP-027666/O-5 F SP  
*(Original report in Portuguese signed by)*

Daniel Marino de Toledo  
Contador CRC 1SP249851/O-8

# Ourofino S.A.

## Balance Sheet as of March 31, 2026 and December 31, 2025

(In thousands of Brazilian reais)



| Assets   | Note | Parent company   |                  | Consolidated     |                  |
|--|------|------------------|------------------|------------------|------------------|
|  |      | 03/31/26         | 12/31/25         | 03/31/26         | 12/31/25         |
| Current assets                                 |      |                  |                  |                  |                  |
| Cash and cash equivalents                      | 5    | 204,768          | 69,354           | 401,103          | 250,821          |
| Trade accounts receivable                      | 6    | 287,797          | 379,822          | 316,532          | 430,367          |
| Inventories and advances to suppliers          | 7    | 108,955          | 98,669           | 344,962          | 312,128          |
| Taxes recoverable                              | 8    | 1,045            | 1,073            | 5,943            | 4,628            |
| Income tax and social contribution recoverable |      | 4,546            | 7,981            | 8,765            | 12,198           |
| Related parties                                | 24   | 340              | 9,649            | 211              | 182              |
| Other assets                                   |      | 6,691            | 5,746            | 20,215           | 13,010           |
| <b>Total current assets</b>                    |      | <b>614,142</b>   | <b>572,294</b>   | <b>1,097,731</b> | <b>1,023,334</b> |
| Non-current                                    |      |                  |                  |                  |                  |
| Taxes recoverable                              | 8    |                  |                  | 1,295            | 1,268            |
| Income tax and social contribution             | 9    | 56,606           | 62,392           | 74,636           | 78,921           |
| Inventories and advances to suppliers          | 7    | 11,284           | 12,310           | 11,284           | 12,310           |
| Other assets                                   |      | 395              | 591              | 1,040            | 1,271            |
| <b>Total long-term receivables</b>             |      | <b>68,285</b>    | <b>75,293</b>    | <b>88,255</b>    | <b>93,770</b>    |
| Investments in subsidiaries                    |      |                  |                  |                  |                  |
| Property, plant and equipment                  | 11   | 9,913            | 9,161            | 340,285          | 342,882          |
| Intangible assets                              | 12   | 443              | 500              | 104,565          | 105,836          |
| <b>Total non-current assets</b>                |      | <b>468,446</b>   | <b>498,781</b>   | <b>533,105</b>   | <b>542,488</b>   |
| <b>Total assets</b>                            |      | <b>1,082,588</b> | <b>1,071,075</b> | <b>1,630,836</b> | <b>1,565,822</b> |

| Liabilities and Equity                              | Note | Parent company   |                  | Consolidated     |                  |
|---|------|------------------|------------------|------------------|------------------|
|   |      | 03/31/26         | 12/31/25         | 03/31/26         | 12/31/25         |
| Current assets                                      |      |                  |                  |                  |                  |
| Trade account payables                              | 13   | 42,763           | 28,393           | 120,319          | 97,332           |
| Derivative financial instruments                    | 26.1 |                  |                  | 268              | 597              |
| Loans and financing                                 | 14   |                  |                  | 57,917           | 52,144           |
| Salaries and payroll charges                        |      | 15,453           | 19,148           | 38,266           | 47,687           |
| Taxes payable                                       |      | 6,916            | 7,697            | 13,724           | 14,988           |
| Income tax and social contribution payable          |      | 2,882            |                  | 2,882            |                  |
| Related parties                                     | 24   | 118,107          | 139,245          | 6,542            | 2,153            |
| Dividends and interest on equity                    | 24   | 52,799           | 52,799           | 52,799           | 52,799           |
| Leases  |      | 5,987            | 6,155            | 7,766            | 7,776            |
| Commissions on sales                                |      | 871              | 1,063            | 909              | 1,218            |
| Other liabilities                                   |      | 3,293            | 2,877            | 15,522           | 11,307           |
| <b>Total current liabilities</b>                    |      | <b>249,071</b>   | <b>257,377</b>   | <b>316,914</b>   | <b>288,001</b>   |
| Non-current   |      |                  |                  |                  |                  |
| Loans and financing                                 | 14   |                  |                  | 453,897          | 437,439          |
| Provision for legal proceedings                     | 15   | 27               | 27               | 4,518            | 4,969            |
| Leases  |      | 2,088            | 1,792            | 6,468            | 6,229            |
| Other liabilities                                   |      | 14,931           | 15,043           | 32,548           | 32,327           |
| <b>Total non-current liabilities</b>                |      | <b>17,046</b>    | <b>16,862</b>    | <b>497,431</b>   | <b>480,964</b>   |
| <b>Total liabilities</b>                            |      | <b>266,117</b>   | <b>274,239</b>   | <b>814,345</b>   | <b>768,965</b>   |
| Equity  |      |                  |                  |                  |                  |
| Capital   | 16   | 479,689          | 479,689          | 479,689          | 479,689          |
| Treasury shares                                     |      | (5,125)          | (5,125)          | (5,125)          | (5,125)          |
| Options granted                                     |      | 6,678            | 6,678            | 6,678            | 6,678            |
| Profit reserve                                      |      | 295,006          | 295,006          | 295,006          | 295,006          |
| Net income for the quarter                          |      | 21,358           |                  | 21,358           |                  |
| Equity valuation adjustments                        |      | 18,865           | 20,588           | 18,865           | 20,588           |
| <b>Total equity of the controlling shareholders</b> |      | <b>816,471</b>   | <b>796,836</b>   | <b>816,471</b>   | <b>796,836</b>   |
| Non-controlling interest                            |      |                  |                  |                  |                  |
|   |      |                  |                  | 20               | 21               |
| <b>Total equity</b>                                 |      | <b>816,471</b>   | <b>796,836</b>   | <b>816,491</b>   | <b>796,857</b>   |
| <b>Total liabilities and equity</b>                 |      | <b>1,082,588</b> | <b>1,071,075</b> | <b>1,630,836</b> | <b>1,565,822</b> |

The accompanying notes are an integral part of these interim individual and consolidated condensed financial statements.



# Ourofino S.A.

## Statement of Profit or Loss

### Quarters ended March 31 2026 and 2025

In thousands of Brazilian reais unless otherwise stated



|   | Note | Parent company |              | Consolidated   |                |
|---|------|----------------|--------------|----------------|----------------|
|   |      | 2026           | 2025         | 2026           | 2025           |
| Revenues  | 17   | 228,374        |              | 250,469        | 189,566        |
| Cost of sales   | 18   | (139,162)      |              | (115,527)      | (97,710)       |
| <b>Gross profit</b>   |      | <b>89,212</b>  |              | <b>134,942</b> | <b>91,856</b>  |
| Selling expenses  | 18   | (49,911)       |              | (63,894)       | (53,249)       |
| Expenses on research and innovation   | 18   |                |              | (18,429)       | (13,028)       |
| General and administrative expenses   | 18   | (7,453)        | (3,033)      | (16,789)       | (15,868)       |
| Equity in the results of investees  | 10   | (1,649)        | 4,080        |                |                |
| Other income (expenses), net  | 19   | (1,259)        | 2            | (1,268)        | (1,139)        |
| <b>Operating profit</b>   |      | <b>28,940</b>  | <b>1,049</b> | <b>34,562</b>  | <b>8,572</b>   |
| Financial revenues  |      | 4,697          | 1,023        | 10,051         | 4,105          |
| Financial expenses  |      | (468)          | (23)         | (11,172)       | (7,901)        |
| Derivative financial instruments, net   |      |                |              | 771            | 114            |
| Foreign exchange variation, net   |      | 36             |              | (982)          | (302)          |
| <b>Financial result</b>   | 20   | <b>4,265</b>   | <b>1,000</b> | <b>(1,332)</b> | <b>(3,984)</b> |
| <b>Income before income tax and social contribution</b>   |      | <b>33,205</b>  | <b>2,049</b> | <b>33,230</b>  | <b>4,588</b>   |
| Income tax and social contribution  | 21   |                |              |                |                |
| Current   |      | (6,061)        |              | (7,679)        | (2,398)        |
| Deferred  |      | (5,786)        |              | (4,194)        | (142)          |
| <b>Net income for the quarter</b>   |      | <b>21,358</b>  | <b>2,049</b> | <b>21,357</b>  | <b>2,048</b>   |
| Attributable to:  |      |                |              |                |                |
| the Company's shareholders  |      |                |              | 21,358         | 2,049          |
| Non-controlling interest  |      |                |              | (1)            | (1)            |
|   |      |                |              | <b>21,357</b>  | <b>2,048</b>   |
| Basic and diluted earnings per share attributable to the Company's shareholders during the quarter (in Brazilian reais) | 22   |                |              | <b>0.39723</b> | <b>0.03811</b> |

The accompanying notes are an integral part of these interim individual and consolidated condensed financial statements.



# Ourofino S.A.

## Statement of Comprehensive Income

### Quarters ended March 31 2026 and 2025

In thousands of Brazilian reais unless otherwise stated



|   | Note | Parent company |              | Consolidated  |              |
|---|------|----------------|--------------|---------------|--------------|
|   |      | 2026           | 2025         | 2026          | 2025         |
| <b>Net income for the quarter</b>                 |      | <b>21,358</b>  | <b>2,049</b> | <b>21,357</b> | <b>2,048</b> |
| Other comprehensive income                        |      |                |              |               |              |
| Items that will be reclassified to profit or loss |      |                |              |               |              |
| Exchange variation on investment                  | 10   | (1,723)        | (1,739)      | (1,723)       | (1,740)      |
| <b>Total comprehensive income for the quarter</b> |      | <b>19,635</b>  | <b>310</b>   | <b>19,634</b> | <b>308</b>   |
| Attributable to:                                  |      |                |              |               |              |
| the Company's shareholders                        |      |                |              | 19,635        | 310          |
| Non-controlling interest                          |      |                |              | (1)           | (2)          |
|   |      |                |              | <b>19,634</b> | <b>308</b>   |

The accompanying notes are an integral part of these interim individual and consolidated condensed financial statements.



# Ourofino S.A.

## Statements of Changes in Equity Quarters ended March 31 2026 and 2025

In thousands of Brazilian reais



| Note   | Attributable to the shareholders of the Parent Company |                 |                              |                |                           |                               |                    |                | Share of the non-controlling shareholders | Total net equity |
|--|--|-----------------|------------------------------|----------------|---------------------------|-------------------------------|--------------------|----------------|---|------------------|
|  | Share capital  | Treasury shares | Long term incentives granted | Profit reserve |                           | Equity assessment adjustments | Accumulated profit | Total          |   |                  |
|  |  |                 |                              | Legal reserve  | Profit retention reserves |                               |                    |                |   |                  |
| <b>As of January 01, 2026</b>                    | <b>479,689</b>   | <b>(5,125)</b>  | <b>6,678</b>                 | <b>47,557</b>  | <b>247,449</b>            | <b>20,588</b>                 |                    | <b>796,836</b> | <b>21</b>                                 | <b>796,857</b>   |
| Comprehensive income for the quarter             |  |                 |                              |                |                           |                               |                    |                |   |                  |
| Net income for the quarter                       |  |                 |                              |                |                           |                               | 21,358             | 21,358         | (1)                                       | 21,357           |
| Exchange variation on investment                 |  |                 |                              |                |                           | (1,723)                       |                    | (1,723)        |   | (1,723)          |
| Total comprehensive income for the quarter       |  |                 |                              |                |                           | (1,723)                       | 21,358             | 19,635         | (1)                                       | 19,634           |
| <b>As of March 31, 2026</b>                      | <b>479,689</b>   | <b>(5,125)</b>  | <b>6,678</b>                 | <b>47,557</b>  | <b>247,449</b>            | <b>18,865</b>                 | <b>21,358</b>      | <b>816,471</b> | <b>20</b>                                 | <b>816,491</b>   |
| <b>As of January 01, 2025</b>                    | <b>599,823</b>   | <b>(5,125)</b>  | <b>7,693</b>                 | <b>36,441</b>  | <b>98,623</b>             | <b>18,943</b>                 |                    | <b>756,398</b> | <b>21</b>                                 | <b>756,419</b>   |
| Comprehensive income for the quarter             |  |                 |                              |                |                           |                               |                    |                |   |                  |
| Net income for the quarter                       |  |                 |                              |                |                           |                               | 2,049              | 2,049          | (1)                                       | 2,048            |
| Exchange variation on investment                 |  |                 |                              |                |                           | (1,739)                       |                    | (1,739)        | (1)                                       | (1,740)          |
| Total comprehensive income for the quarter       |  |                 |                              |                |                           | (1,739)                       | 2,049              | 310            | (2)                                       | 308              |
| Contributions and distributions to shareholders: |  |                 |                              |                |                           |                               |                    |                |   |                  |
| Return of capital to shareholders                | 16 (a)   | (120,134)       |                              |                |                           |                               |                    | (120,134)      |   | (120,134)        |
| Long-term incentive granted                      | 16 (d)   |                 | (1,015)                      |                |                           |                               |                    | (1,015)        |   | (1,015)          |
| Total shareholder contributions                  |  | (120,134)       | (1,015)                      |                |                           |                               |                    | (121,149)      |   | (121,149)        |
| <b>As of March 31, 2025</b>                      | <b>479,689</b>   | <b>(5,125)</b>  | <b>6,678</b>                 | <b>36,441</b>  | <b>98,623</b>             | <b>17,204</b>                 | <b>2,049</b>       | <b>635,559</b> | <b>19</b>                                 | <b>635,578</b>   |

The accompanying notes are an integral part of these interim individual and consolidated condensed financial statements.



# Ourofino S.A.

## Statement of Cash Flows

### Quarters ended March 31 2026 and 2025

In thousands of Brazilian reais unless otherwise stated



|  | Note      | Parent company |                  | Consolidated   |                  |
|--|-----------|----------------|------------------|----------------|------------------|
|  |           | 2026           | 2025             | 2026           | 2025             |
| <b>Net income for the quarter</b>                            |           | <b>21,358</b>  | <b>2,049</b>     | <b>21,357</b>  | <b>2,048</b>     |
| Adjustments for:   |           |                |                  |                |                  |
| Current and deferred income tax and social contribution      | 21        | 11,847         |                  | 11,873         | 2,540            |
| Expected credit gains (losses)                               | 6         | 247            |                  | 247            | (7)              |
| Provision for inventory losses and write-offs                |           | 2,529          |                  | 3,189          | 6,940            |
| Equity in the results of investees                           | 10        | 1,649          | (4,080)          |                |                  |
| Depreciation and amortization                                | 11 and 12 | 1,601          | 17               | 10,007         | 9,422            |
| Provision for impairment of intangible assets                | 11        |                |                  | (14)           | 652              |
| Gain (loss) on disposal of property, plant and equipment     | 19        | (5)            |                  | (81)           | (74)             |
| Gain (loss) on disposal of intangible assets                 | 19        |                |                  | 20             | (333)            |
| Interest and monetary/foreign exchange variations, net       |           | 7              | 3                | 8,113          | 5,725            |
| Derivative financial instruments                             | 20        |                |                  | (771)          | (114)            |
| Provision (reversal) for legal proceedings                   | 15        |                |                  | (441)          | 45               |
| Long-term incentives   |           | (113)          | 620              | 221            | 1,673            |
| Fair value adjustment  |           | 402            |                  | 706            | 626              |
| Changes in working capital:                                  |           |                |                  |                |                  |
| Trade accounts receivable                                    |           | 90,927         | (58)             | 209,877        | 111,990          |
| Inventories and advances to suppliers                        |           | (10,830)       |                  | (35,053)       | (79,576)         |
| Taxes recoverable  |           | (247)          | 532              | (1,721)        | (2,245)          |
| Other assets   |           | (1,759)        | (81)             | (8,051)        | (9,034)          |
| Trade accounts payable                                       |           | (6,772)        | (288)            | (69,732)       | 30,877           |
| Taxes payable  |           | 2,634          | (4,016)          | 529            | (4,120)          |
| Other liabilities  |           | (2,612)        | (1,056)          | (4,054)        | (6,394)          |
| Interest paid on loans and financing                         | 25        |                |                  | (7,394)        | (5,469)          |
| Interest paid on leases                                      |           | (446)          | (4)              | (675)          | (447)            |
| Income tax and social contribution paid                      |           | (2,885)        | (382)            | (2,885)        | (7,051)          |
| <b>Net cash from (used in) operating activities</b>          |           | <b>107,532</b> | <b>(6,744)</b>   | <b>135,267</b> | <b>57,674</b>    |
| Cash flows from investing activities:                        |           |                |                  |                |                  |
| Investment in intangible assets                              | 12        |                |                  | (1,500)        | (5,710)          |
| Purchase of property, plant and equipment                    | 11        | (665)          |                  | (2,772)        | (5,123)          |
| Distribution of dividends and interest on equity (i)         |           | 30,000         | 15,000           |                |                  |
| Proceeds from sale of property, plant and equipment          |           | 5              |                  | 173            | 194              |
| Amount received from the sale of intangible assets           |           |                |                  |                | 333              |
| <b>Net cash from (used in) investing activities</b>          |           | <b>29,340</b>  | <b>15,000</b>    | <b>(4,099)</b> | <b>(10,306)</b>  |
| Cash flows from financing activities:                        |           |                |                  |                |                  |
| New loans and financing                                      | 25        |                |                  | 29,992         |                  |
| Repayments of loan and financing                             | 25        |                |                  | (8,981)        | (10,622)         |
| Lease payments   |           | (1,458)        | (17)             | (2,169)        | (1,688)          |
| Return of capital to shareholders                            | 16 (a)    |                | (120,134)        |                | (120,134)        |
| Realized derivative financial instruments                    |           |                |                  | 443            | (167)            |
| <b>Net cash from (used in) financing activities</b>          |           | <b>(1,458)</b> | <b>(120,151)</b> | <b>19,285</b>  | <b>(132,611)</b> |
| <b>Increase (decrease) in cash and cash equivalents, net</b> |           | <b>135,414</b> | <b>(111,895)</b> | <b>150,453</b> | <b>(85,243)</b>  |
| Cash and cash equivalents at the beginning of the quarter    |           | 69,354         | 120,710          | 250,821        | 233,957          |
| Foreign exchange losses on cash and cash equivalents         |           |                |                  | (171)          | (212)            |
| <b>Cash and cash equivalents at the end of the quarter</b>   | 5         | <b>204,768</b> | <b>8,815</b>     | <b>401,103</b> | <b>148,502</b>   |

(i) Income from dividends and interest on equity in the Parent Company is classified as investing activities as it refers to returns on investments.

Non-cash transactions in financing activities are presented in Note 25.

The accompanying notes are an integral part of these interim individual and consolidated condensed financial statements.



# Ourofino S.A.

## Statements of Value Added

### Quarters ended March 31 2026 and 2025

In thousands of Brazilian reais unless otherwise stated



|   | Note      | Parent company |              | Consolidated   |                |
|---|-----------|----------------|--------------|----------------|----------------|
|   |           | 2026           | 2025         | 2026           | 2025           |
| Revenues:   |           |                |              |                |                |
| Gross revenues from sales and services                      |           | 247,931        |              | 277,876        | 209,572        |
| Other revenues, net   |           | (201)          |              | 615            | 352            |
| Income from construction of own assets                      |           |                |              | 1,496          | 4,804          |
| Expected credit gains (losses)                              |           | (247)          |              | (247)          | 7              |
|   |           | <b>247,483</b> |              | <b>279,740</b> | <b>214,735</b> |
| Inputs acquired from third parties:                         |           |                |              |                |                |
| Cost of sales and services                                  |           | (148,510)      |              | (80,795)       | (71,344)       |
| Materials, electricity, third-party services and other      |           | (28,441)       | (536)        | (58,619)       | (53,957)       |
| Losses on assets, net                                       |           | (2,506)        |              | (3,393)        | (7,331)        |
|   |           |                |              |                |                |
| <b>Gross value added (distributed)</b>                      |           | <b>68,026</b>  | <b>(536)</b> | <b>136,933</b> | <b>82,103</b>  |
| Depreciation and amortization                               | 11 and 12 | (1,601)        | (17)         | (10,007)       | (9,422)        |
| <b>Net value added (distributed) produced by the entity</b> |           | <b>66,425</b>  | <b>(553)</b> | <b>126,926</b> | <b>72,681</b>  |
| Value added received through transfer:                      |           |                |              |                |                |
| Equity in the results of investees                          | 10        | (1,649)        | 4,080        |                |                |
| Finance income  |           | 4,895          | 1,111        | 13,090         | 6,021          |
| Royalties   |           | 50             | 50           | 50             | 51             |
| Other   |           | 45             | 2            | 174            | 189            |
|   |           |                |              |                |                |
| <b>Total value added to be distributed</b>                  |           | <b>69,766</b>  | <b>4,690</b> | <b>140,240</b> | <b>78,942</b>  |
| <b>Distribution of value added</b>                          |           |                |              |                |                |
| Personnel:  |           |                |              |                |                |
| Direct compensation   |           | 18,874         | 1,860        | 43,524         | 40,645         |
| Benefits  |           | 2,168          | 44           | 8,030          | 7,075          |
| FGTS  |           | 1,419          | 31           | 3,001          | 2,597          |
| Taxes, charges and contributions:                           |           |                |              |                |                |
| Federal   |           | 20,120         | 679          | 35,798         | 11,922         |
| State   |           | 5,136          | 3            | 12,745         | 3,935          |
| Municipal   |           |                | 1            | 192            | 162            |
| Remuneration of third parties' capital:                     |           |                |              |                |                |
| Interests   |           | 432            | 23           | 14,078         | 9,785          |
| Rentals   |           | 216            |              | 1,272          | 674            |
| Other   |           | 43             |              | 243            | 99             |
| Equity remuneration   |           |                |              |                |                |
| Retained earnings   |           | 21,358         | 2,049        | 21,358         | 2,049          |
| Non-controlling interest                                    |           |                |              | (1)            | (1)            |
|   |           |                |              |                |                |
| <b>Value added distributed</b>                              |           | <b>69,766</b>  | <b>4,690</b> | <b>140,240</b> | <b>78,942</b>  |

The accompanying notes are an integral part of these interim individual and consolidated condensed financial statements.





### 1. General Information

Ouro Fino S.A. (the "Company") is a publicly-held corporation headquartered in the city of Cravinhos, State of São Paulo. The Company's shares are traded in the Brazilian stock exchange, B3 S.A. - Brasil, Bolsa, Balcão.

The Company and its subsidiaries (collectively, the "Group") operate in the animal health industry, specifically in the development, production and sale of veterinary drugs, vaccines and other products for production and companion animals.

At an Extraordinary General Meeting held on July 17, 2024, the Company's shareholders approved, among other matters, the change of the corporate name from "Ouro Fino Saúde Animal Participações S.A." to "Ourofino S.A." and the addition of activities existing in the Company's corporate purpose.

At this same Meeting, the "Incorporation Protocol and Justification" of the subsidiary Ouro Fino Agronegócio Ltda. by the Company was approved ("OF Agro") by its parent company, Ourofino S.A. (the "Company"), the completion of which was subject to the fulfillment of certain precedent conditions.

As a result of this transaction, Management hired independent specialists to prepare the accounting valuation report, based on the equity value of OF Agro as of August 31, 2025, in the amount of R\$295,954, as shown in the table below:

| Assets   | 08/31/25       | Liabilities and Equity               | 08/31/25       |
|--|----------------|--------------------------------------|----------------|
| Current  |                | Current                              |                |
| Cash and cash equivalents                      | 36,254         | Trade accounts payable               | 158,307        |
| Trade accounts receivable                      | 313,734        | Salaries and payroll charges         | 19,071         |
| Inventories                                    | 149,436        | Taxes payable                        | 6,250          |
| Taxes recoverable                              | 1,163          | Income tax and social contribution   | 18,278         |
| Income tax and social contribution recoverable | 5,808          | Dividends and interest on equity     | 15,165         |
| Other assets                                   | 2,708          | Commissions on sales                 | 1,725          |
| <b>Total current assets</b>                    | <b>509,103</b> | Other liabilities                    | 8,530          |
|  |                | <b>Total current liabilities</b>     | <b>227,325</b> |
| Non-current                                    |                | Non-current                          |                |
| Long-term receivables                          |                | Provision for legal proceedings      | 23             |
| Income tax and social contribution deferred    | 9,438          | Other liabilities                    | 6,146          |
| Other assets                                   | 360            | <b>Total non-current liabilities</b> | <b>6,170</b>   |
| <b>Total non-current assets</b>                | <b>9,798</b>   | <b>Total liabilities</b>             | <b>233,495</b> |
|  |                | Equity                               |                |
| Property, plant and equipment                  | 9,970          | Share capital                        | 141,543        |
| Intangible assets                              | 577            | Options granted                      | 845            |
| <b>Total non-current assets</b>                | <b>20,346</b>  | Retained earnings                    | 153,566        |
|  |                | <b>Total equity</b>                  | <b>295,954</b> |
| <b>Total assets</b>                            | <b>529,449</b> | <b>Total liabilities and equity</b>  | <b>529,449</b> |

In this context, after all the conditions had been met, the transaction was completed on October 1, 2025, data at which the Company fully absorbed the assets and liabilities balances of OF Agro.





The incorporated balances were based on the closing as of September 30, 2025, as shown in the balance sheet below.

| Assets   | 09/30/25       | Liabilities and Equity               | 09/30/25       |
|--|----------------|--------------------------------------|----------------|
| Current  |                | Current                              |                |
| Cash and cash equivalents                      | 15,396         | Trade accounts payable               | 169,095        |
| Trade accounts receivable                      | 299,790        | Salaries and payroll charges         | 20,086         |
| Inventories                                    | 171,819        | Taxes payable                        | 5,241          |
| Taxes recoverable                              | 1,230          | Income tax and social contribution   | 13,946         |
| Income tax and social contribution recoverable | 5,808          | Commissions on sales                 | 950            |
| Other assets                                   | 4,346          | Other liabilities                    | 7,889          |
| <b>Total current assets</b>                    | <b>498,389</b> | <b>Total current liabilities</b>     | <b>217,206</b> |
| Non-current                                    |                | Non-current                          |                |
| Long-term receivables                          |                | Provision for legal proceedings      | 26             |
| Income tax and social contribution deferred    | 9,255          | Other liabilities                    | 5,130          |
| Other assets                                   | 322            | <b>Total non-current liabilities</b> | <b>5,157</b>   |
| <b>Total non-current assets</b>                | <b>9,577</b>   | <b>Total liabilities</b>             | <b>222,363</b> |
| Property, plant and equipment                  | 10,030         | Equity                               |                |
| Intangible assets                              | 558            | Share capital                        | 141,543        |
| <b>Total non-current assets</b>                | <b>20,166</b>  | Options granted                      | 845            |
|  |                | Retained earnings                    | 153,804        |
|  |                | <b>Total equity</b>                  | <b>296,192</b> |
| <b>Total assets</b>                            | <b>518,555</b> | <b>Total liabilities and equity</b>  | <b>518,555</b> |

As a result, OF Agro was dissolved, and the Company proceeded with the derecognition of the investment previously recorded in its balance sheet, in the amount of R\$296,192.

The difference between the amounts in the valuation report and those recorded at the date of the merger arises from different reference periods, since the report was prepared one month prior to the effective date of the transaction.

### Tax Reform

On January 16, 2025, Complementary Law No. 214 was enacted, representing the first phase of regulation of the Tax Reform. The new model establishes a Value Added Tax (VAT) structured under two jurisdictions ("dual VAT"): Federal, through the Contribution on Goods and Services (CBS), and Subnational, through the Tax on Goods and Services (IBS). These taxes will replace PIS, COFINS, ICMS, and ISS.

Additionally, a Selective Tax (IS) was introduced at the federal level, levied on the production, extraction, sale, or import of goods and services deemed harmful to health or the environment, as defined by supplementary regulation.

The transition period will take place from 2026 to 2032, during which the current tax system will coexist with the new regime. The impacts of the Reform on the calculation of the aforementioned taxes can only be effectively assessed after the completion of the regulation of the matters still pending through a Complementary Law.

As of the quarter ended March 31, 2026, there are no impacts arising from the Tax Reform reflected in the condensed interim financial statements presented at this date.





### 2. List of subsidiaries

The consolidated financial statements include the financial statements of the Company and its subsidiaries prepared for each period. Control is obtained when the Company: (i) holds the power on the investee; (ii) is exposed to or has rights to variable returns as a result of its involvement with the investee and (iii) has the ability to provide direction to the significant activities of the investee.

The Group's subsidiaries are listed below.

| Name                                  | Country  | Business   | 03/31/26        |                | 12/31/25   |  |
|---------------------------------------|----------|--|-----------------|----------------|--|--|
|                                       |          |  | Direct interest | Share Indirect | Direct interest  | Share Indirect   |
| (i) Ouro Fino Saúde Animal Ltda.      | Brazil   | Operates in the research, development, production and sale of veterinary drugs, vaccines and other products. Commercialization in the domestic market was carried out, until September 30, 2025, by the company mentioned in item (ii) and, as from October 1, 2025, began to be conducted by the parent company, Ourofino S.A. Commercialization in the foreign market is carried out directly with third parties, as well as through the companies mentioned in items (iii) and (iv). The company also manufactures to third parties upon order. | 100.00%         |                | 100.00%  |  |
| (ii) Ouro Fino Agronegócio Ltda.      | Brazil   | It operated in the commercialization, in the domestic market, of veterinary drugs, vaccines, and other veterinary products intended for production animals and companion animals, acquired from the company mentioned in items (i) and (v), as well as from third parties. On October 1, 2025, the company was merged into its parent company.   |                 |                | Merged into Ourofino S.A. on October 1, 2025 (Note 1). |  |
| (iii) Ouro Fino de México, S.A. de CV | Mexico   | Operates in the sales, exclusively in Mexico, of veterinary drugs and other products purchased from the company mentioned in item (i).   |                 | 99.92%         |  | 99.92%   |
| (iv) Ouro Fino Colômbia S.A.S         | Colombia | Operates in the sales, exclusively in Colombia, of veterinary drugs and other products purchased from the company mentioned in item (i).   |                 | 100.00%        |  | 100.00%  |
| (v) Regenera Medicina Avançada Ltda.  | Brazil   | It operated in research, development, manufacturing, and trade of therapeutic protocols involving mesenchymal stem cells and derivatives for companion animals. On May 1, 2025, the company was merged into its parent company.  |                 |                |  | Merged into Ouro Fino Saúde Animal Ltda. on May 1, 2025. |





### 3. Basis of preparation

#### **Statement of compliance (with IFRS and accounting practices adopted in Brazil)**

The interim condensed financial statements were prepared in accordance with the Brazilian technical pronouncement CPC 21 (R1) - Interim Financial Reporting, and with international accounting standard IAS 34 - "Interim Financial Reporting", issued by the International Accounting Standards Board - (IASB), and are presented in accordance with the standards issued by the Brazilian Securities Commission (CVM) applicable to the preparation of Quarterly Statements (ITR).

The accounting policies adopted in Brazil comprise those included in Brazilian Corporate Law and technical pronouncements, guidelines and interpretations issued by the Accounting Pronouncements Committee - CPC, which were approved by the Federal Accounting Board - CFC and the Brazilian Securities and Exchange Commission - CVM.

These condensed interim financial statements have been prepared using the same basis of preparation and accounting policies consistent with those adopted in the preparation of the financial statements as of December 31, 2025, and should be read in conjunction with those financial statements.

The explanatory note disclosures that did not undergo significant changes or that involved immaterial events and transactions compared to December 31, 2025, have not been fully repeated in these condensed interim financial statements. However, selected information has been included to explain the main events and transactions that occurred, in order to provide an understanding of the changes in the financial position and operating performance of the Company and its subsidiaries since the publication of the December 31, 2025 financial statements.

As there is no difference between the consolidated equity and the consolidated income attributable to the shareholders of the parent company and the parent company's equity and income, included in the individual and consolidated financial statements prepared in compliance with IFRSs and accounting practices adopted in Brazil, the Company decided to present these individual and consolidated financial statements in a single set, side by side.

In preparing these individual and consolidated condensed interim financial statements, Management made judgments, estimates, and assumptions that affect the application of the Company's accounting policies and the reported amounts of assets, liabilities, revenues, and expenses. Actual results may differ from these estimates. The estimates and assumptions are continuously reviewed and have not undergone any significant changes in the preparation of these interim financial statements compared to the financial statements as of December 31, 2025.

All relevant information pertaining to the financial statements, and only such information, is being disclosed and corresponds to that used by Management in its operations.

The presentation of the individual and consolidated statements of value added ("SVA") is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies. The SVA has been prepared in compliance with the criteria defined in Technical Pronouncement CPC 09 - Statement of Value Added. IFRSs do not require the presentation of this statement and, as a result, under IFRS, the presentation of such statement is considered supplementary information, without prejudice of the set of interim condensed financial statements.

The issue of this individual and consolidated interim condensed financial statements was authorized for disclosing by the Board of Directors on May 5, 2026.





#### 4. Functional and reporting currency

These financial statements are presented in Brazilian Real, which is the functional currency of the Company and its subsidiaries. All balances have been rounded to the nearest thousand, except when otherwise noted. The accounting information of each subsidiary included in the Company's consolidation, as well as that used as the basis for investment valuation under the equity method, is prepared using the functional currency of each entity.

#### 5. Cash and cash equivalents

These comprise cash on hand and at banks, as well as financial investments consisting of Repurchase Agreements (Repos) and CDBs, yielding on average 99.16% of the Interbank Deposit Certificate (CDI) rate variation (December 31, 2025 - average of 98.18% of CDI rate).

|  | Parent company |               | Consolidated   |                |
|--|----------------|---------------|----------------|----------------|
|  | 03/31/26       | 12/31/25      | 03/31/26       | 12/31/25       |
| Cash:  |                |               |                |                |
| In local currency                                      | 3              | 3             | 5              | 13             |
| In foreign currency                                    | 43             | 46            | 72             | 76             |
|  | 46             | 49            | 77             | 89             |
| Banks:   |                |               |                |                |
| In local currency                                      | 4,260          | 7,161         | 8,225          | 13,631         |
| In foreign currency                                    |                |               | 14,905         | 6,572          |
|  | 4,260          | 7,161         | 23,130         | 20,203         |
| Financial investments - cash and cash equivalents (i): |                |               |                |                |
| In local currency                                      |                |               |                |                |
| Bank Deposit Certificate (CDB)                         | 183,109        | 2,890         | 339,212        | 151,959        |
| Repo and others  | 17,353         | 59,254        | 38,684         | 78,570         |
|  | 200,462        | 62,144        | 377,896        | 230,529        |
| <b>Total cash and cash equivalents</b>                 | <b>204,768</b> | <b>69,354</b> | <b>401,103</b> | <b>250,821</b> |

(i) Financial investments as cash equivalents in the amount of R\$377,896 (R\$230,529 as of December 31, 2025) are mainly aimed at maintaining the Group's liquidity to cover the needs of operating activities. Such investments include the feature of immediate redemption with no loss of profitability.




**6. Trade accounts receivable**

|                        | Parent company |                | Consolidated   |                |
|------------------------|----------------|----------------|----------------|----------------|
|                        | 03/31/26       | 12/31/25       | 03/31/26       | 12/31/25       |
| In local currency      |                |                |                |                |
| Accounts receivable    | 289,487        | 381,265        | 305,317        | 405,288        |
| Expected credit losses | (1,690)        | (1,443)        | (1,970)        | (1,730)        |
|                        | 287,797        | 379,822        | 303,347        | 403,558        |
| In foreign currency    |                |                |                |                |
| Accounts receivable    |                |                | 13,185         | 26,809         |
|                        | -              | -              | 13,185         | 26,809         |
| <b>Current</b>         | <b>287,797</b> | <b>379,822</b> | <b>316,532</b> | <b>430,367</b> |

The analysis of the maturity of trade receivables is as follows:

|                          | Parent company |                | Consolidated   |                |
|--------------------------|----------------|----------------|----------------|----------------|
|                          | 03/31/26       | 12/31/25       | 03/31/26       | 12/31/25       |
| To be due:               |                |                |                |                |
| Up to three months       | 237,219        | 283,228        | 260,577        | 328,538        |
| From three to six months | 47,456         | 85,970         | 50,081         | 92,598         |
| Over six months          | 1,445          | 6,588          | 1,445          | 6,588          |
|                          | 286,120        | 375,786        | 312,103        | 427,724        |
| Past due:                |                |                |                |                |
| Up to three months       | 1,678          | 4,079          | 4,102          | 2,728          |
| From three to six months | 5              | 87             | 332            | 161            |
| Over six months          | 1,684          | 1,313          | 1,965          | 1,484          |
|                          | 3,367          | 5,479          | 6,399          | 4,373          |
|                          | <b>289,487</b> | <b>381,265</b> | <b>318,502</b> | <b>432,097</b> |

The Group's Executive Board has adopted the measurement of expected credit losses based on the lifetime of the instruments, using the simplified approach, considering the history of changes and losses. As a general rule, notes overdue over 180 days represent a significant indication of loss, and are assessed individually, considering existing guarantees.

Changes in allowance for expected losses were as follows:

|                            | Parent company | Consolidated |              |
|----------------------------|----------------|--------------|--------------|
|                            | 03/31/26       | 03/31/26     | 03/31/25     |
| Opening balance            | 1,443          | 1,730        | 1,375        |
| Additions (reversals), net | 247            | 247          | (7)          |
| Write-Offs                 |                |              | (2)          |
| Foreign exchange variation |                | (7)          |              |
| <b>Closing balance</b>     | <b>1,690</b>   | <b>1,970</b> | <b>1,366</b> |

Additions to and reversals of the expected credit losses on account receivables were recorded in the statement of profit or loss for the quarter under "Selling expenses" (Note





18). The Group's Executive Board analyzes on an annual basis the provisioned balance and the amounts are written off from the provision account when there is no expectation of recovering the funds.

### 7. Inventories and Advances to Suppliers

|   | Parent company |               | Consolidated   |                |
|---|----------------|---------------|----------------|----------------|
|   | 03/31/26       | 12/31/25      | 03/31/26       | 12/31/25       |
| Finished goods                              | 91,153         | 87,401        | 156,113        | 130,596        |
| Raw materials                               |                |               | 83,635         | 89,239         |
| Packaging materials                         |                |               | 21,529         | 22,622         |
| Semi-finished and work-in-progress products |                |               | 13,643         | 14,669         |
| Auxiliary production materials              |                |               | 13,120         | 13,573         |
| Imports in transit                          | 8,091          | 1,390         | 38,638         | 22,442         |
| Advances to suppliers                       | 8,593          | 6,806         | 10,128         | 8,486          |
| Others                                      | 1,118          | 3,072         | 8,156          | 10,501         |
| <b>Total current</b>                        | <b>108,955</b> | <b>98,669</b> | <b>344,962</b> | <b>312,128</b> |
| Advances to suppliers                       | 11,284         | 12,310        | 11,284         | 12,310         |
| <b>Total non-current</b>                    | <b>11,284</b>  | <b>12,310</b> | <b>11,284</b>  | <b>12,310</b>  |

Inventories have been written down to net realizable value. The reductions in accounting balances and reversals are included in "Cost of Sales" in the statement of profit or loss.

The change in provisions for inventory losses is presented below:

|                            | Parent company |               | Consolidated  |          |
|----------------------------|----------------|---------------|---------------|----------|
|                            | 03/31/26       | 12/31/25      | 03/31/26      | 03/31/25 |
| Opening balance            | 9,985          | 30,551        | 38,508        |          |
| Additions, net             | 2,511          | 3,554         | 5,835         |          |
| Write-Offs                 | (352)          | (2,287)       | (4,275)       |          |
| Foreign exchange variation |                | (162)         | (72)          |          |
| <b>Closing balance</b>     | <b>12,144</b>  | <b>31,656</b> | <b>39,996</b> |          |

### 8. Taxes recoverable

|  | Parent company |              | Consolidated |              |
|--|----------------|--------------|--------------|--------------|
|  | 03/31/26       | 12/31/25     | 03/31/26     | 12/31/25     |
| Value-Added Tax on Sales and Services (ICMS) | 224            | 224          | 224          | 3,497        |
| IRRF   |                |              | 800          |              |
| PIS and COFINS                               |                |              |              | 557          |
| ICMS, PIS and COFINS on purchase of PPE      |                |              | 1,152        | 438          |
| Excise Tax (IPI)                             | 155            | 184          | 713          | 184          |
| Others                                       | 666            | 665          | 4,349        | 1,220        |
| <b>Total</b>                                 | <b>1,045</b>   | <b>1,073</b> | <b>7,238</b> | <b>5,896</b> |
| Current assets                               | 1,045          | 1,073        | 5,943        | 4,628        |
| Non-current                                  |                |              | 1,295        | 1,268        |




**9. Deferred Income Tax and Social Contribution**

## a) Composition, nature and realization of deferred taxes

|   | Parent company |               | Consolidated    |                 |
|---|----------------|---------------|-----------------|-----------------|
|   | 03/31/26       | 12/31/25      | 03/31/26        | 12/31/25        |
| Tax credits on:   |                |               |                 |                 |
| Accumulated income tax and social contribution losses   | 41,745         | 44,345        | 45,433          | 44,345          |
| Temporary differences                                   |                |               |                 |                 |
| Provisions  | 14,861         | 18,047        | 39,254          | 44,224          |
| <i>Provision for inventory losses</i>                   | 4,129          | 3,395         | 12,202          | 10,734          |
| <i>Provisions for personnel expenses</i>                | 6,470          | 8,085         | 13,692          | 17,147          |
| <i>Provision for commissions</i>                        | 1,536          | 1,246         | 1,549           | 1,299           |
| <i>Provision for legal proceedings</i>                  | 9              | 9             | 1,536           | 1,547           |
| <i>Provision for impairment of intangible assets</i>    | 416            | 416           | 4,477           | 4,481           |
| <i>Provision for expected losses</i>                    | 246            | 227           | 246             | 227             |
| <i>Other</i>  | 2,055          | 4,669         | 5,552           | 8,789           |
| Unrealized profit on inventories                        |                |               | 10,604          | 10,646          |
|   | <b>56,606</b>  | <b>62,392</b> | <b>95,291</b>   | <b>99,215</b>   |
| Tax debits on:  |                |               |                 |                 |
| Temporary differences                                   |                |               |                 |                 |
| Deemed cost of lands                                    |                |               | (7,878)         | (7,878)         |
| Expenditure on internally generated assets (Lei do Bem) |                |               | (12,777)        | (12,416)        |
|   | -              | -             | <b>(20,655)</b> | <b>(20,294)</b> |
| <b>Total assets, net</b>                                | <b>56,606</b>  | <b>62,392</b> | <b>74,636</b>   | <b>78,921</b>   |

Deferred income tax and social contribution are presented net, by entity, in the balance sheet.

Net changes in the deferred income tax and social contribution accounts was determined as follows:

|   | Parent company | Consolidated  |               |
|---|----------------|---------------|---------------|
|   | 03/31/26       | 03/31/26      | 03/31/25      |
| Opening balance                                       | 62,392         | 78,921        | 31,284        |
| Accumulated income tax and social contribution losses | (2,600)        | 1,088         | 2,279         |
| Provisions  | (3,186)        | (4,879)       | (4,742)       |
| Unrealized profit on inventories                      |                | (42)          | 2,133         |
| Expenditure on internally generated assets            |                | (361)         | 62            |
| Revaluation surplus - business combination (*)        |                |               | (26)          |
| Foreign exchange variation (*)                        |                | (91)          | 76            |
| <b>Closing balance</b>                                | <b>56,606</b>  | <b>74,636</b> | <b>31,066</b> |

(\*) Refers to the translation adjustment of the subsidiaries Ouro Fino de México, S.A. de CV and Ouro Fino Colombia S.A.S recognized in equity, in addition to the reversal of the fair value surplus of the subsidiary Ouro Fino Colômbia S.A.S.

## b) Tax loss carryforwards

Until December 31, 2024, at the parent company level, deferred tax assets on accumulated tax losses and negative bases were not recognized, as it was not probable that future taxable profits would be available for the Company to realize such benefits.





As mentioned in Note 1, after the fulfillment of all established conditions, the parent company absorbed, through a merger, the balances of assets and liabilities of OF Agro, and the transaction was completed on October 1, 2025. As a result, the parent company commenced its operating activities, and Management revised its estimates of future taxable profits. In this context, at the end of the fiscal year ended December 31, 2025, the Group recognized deferred tax assets of R\$49,598 related to previously unrecognized tax losses and negative bases, as Management considered it probable that future taxable profits would be available against which such losses could be utilized.

## 10. Investments (Parent Company)

### a) Changes in investments

|  | Parent company |                |
|--|----------------|----------------|
|  | 03/31/26       | 03/31/25       |
| Opening balance                          | 413,827        | 641,141        |
| Equity in the results of investees       | (1,649)        | 4,080          |
| Long-term incentive                      |                | (627)          |
| Dividends received (i)                   | (20,650)       | (15,000)       |
| Exchange variation on foreign investment | (1,723)        | (1,739)        |
| <b>Closing balance</b>                   | <b>389,805</b> | <b>627,855</b> |

- (i) In the quarter ended March 31, 2026, the shareholders of the subsidiary Ouro Fino Saúde Animal Ltda. approved and distributed dividends to the parent company Ourofino S.A. in the amount of R\$20,650 (December 31, 2025 – R\$10,000 (Ouro Fino Saúde Animal Ltda.) and R\$5,000 (Ouro Fino Agronegócio Ltda., merged into the Parent on October 1, 2025 – Note 1)).





b) Summarized financial information

The tables below present summarized financial information of the subsidiaries.

|                                       | 03/31/26                     |                                   |                          |
|---------------------------------------|------------------------------|-----------------------------------|--------------------------|
|                                       | Subsidiaries                 |                                   |                          |
|                                       | Direct                       | Indirect                          |                          |
|                                       | Ouro Fino Saúde Animal Ltda. | Ouro Fino de México, S.A. de C.V. | Ouro Fino Colômbia S.A.S |
| Current                               |                              |                                   |                          |
| Assets                                | 577,039                      | 28,749                            | 37,680                   |
| Liabilities                           | (164,243)                    | (7,944)                           | (24,348)                 |
| Current assets, net                   | 412,796                      | 20,805                            | 13,332                   |
| Non-current                           |                              |                                   |                          |
| Assets                                | 475,964                      | 2,461                             | 4,666                    |
| Liabilities                           | (478,371)                    |                                   | (2,014)                  |
| Non-current assets (liabilities), net | (2,407)                      | 2,461                             | 2,652                    |
| <b>Equity</b>                         | <b>410,389</b>               | <b>23,266</b>                     | <b>15,984</b>            |

|                         | 12/31/2025                   |                                   |                          |
|-------------------------|------------------------------|-----------------------------------|--------------------------|
|                         | Subsidiaries                 |                                   |                          |
|                         | Direct                       | Indirect                          |                          |
|                         | Ouro Fino Saúde Animal Ltda. | Ouro Fino de México, S.A. de C.V. | Ouro Fino Colômbia S.A.S |
| Current                 |                              |                                   |                          |
| Assets                  | 575,040                      | 31,168                            | 38,285                   |
| Liabilities             | (158,691)                    | (8,414)                           | (25,659)                 |
| Current assets, net     | 416,349                      | 22,754                            | 12,626                   |
| Non-current             |                              |                                   |                          |
| Assets                  | 479,825                      | 2,516                             | 5,129                    |
| Liabilities             | (461,681)                    |                                   | (2,422)                  |
| Non-current assets, net | 18,144                       | 2,516                             | 2,707                    |
| <b>Equity</b>           | <b>434,493</b>               | <b>25,270</b>                     | <b>15,333</b>            |





### c) Reconciliation of the financial statements on investments

|  | Subsidiaries                 |                |                                      |                |                |
|--|------------------------------|----------------|--------------------------------------|----------------|----------------|
|  | Ouro Fino Saúde Animal Ltda. |                | Ouro Fino Agronegócio Ltda. (Note 2) | Total          |                |
|  | 03/31/26                     | 03/31/25       | 03/31/25                             | 03/31/26       | 03/31/25       |
| Equity as of January 1                                     | 434,493                      | 428,837        | 228,355                              | 434,493        | 657,192        |
| Net income for the quarter                                 | (1,731)                      | (1,159)        | 9,380                                | (1,731)        | 8,221          |
| Long-term incentive  |                              | (485)          | (142)                                |                | (627)          |
| Dividends paid   | (20,650)                     | (10,000)       | (5,000)                              | (20,650)       | (15,000)       |
| Exchange variation on foreign investment                   | (1,723)                      | (1,739)        |                                      | (1,723)        | (1,739)        |
| <b>Equity as of March 31</b>                               | <b>410,389</b>               | <b>415,454</b> | <b>232,593</b>                       | <b>410,389</b> | <b>648,047</b> |
| Percentage equity interest - %                             | 100.00%                      | 99.99%         | 100.00%                              |                |                |
| Share of investments                                       | 410,389                      | 415,454        | 232,593                              | 410,389        | 648,047        |
| Unrealized profit on inventories                           | (20,584)                     | (20,192)       |                                      | (20,584)       | (20,192)       |
| <b>Carrying amount of the investment in Parent Company</b> | <b>389,805</b>               | <b>395,262</b> | <b>232,593</b>                       | <b>389,805</b> | <b>627,855</b> |

## 11. Property, plant and equipment

### (i) Parent company

| Change:  | As of January 01, 2026 | Additions    | Write-Offs   | Depreciation   | As of March 31, 2026 |
|--|------------------------|--------------|--------------|----------------|----------------------|
| Right of Use - Leases (i)                      | 6,634                  | 1,761        | (130)        | (1,415)        | 6,850                |
| Buildings and improvements                     | 976                    |              |              | (19)           | 957                  |
| Machinery, equipment and industrial facilities | 265                    |              |              | (10)           | 255                  |
| Vehicles and tractors                          | 377                    |              |              | (34)           | 343                  |
| Furniture and fixtures                         | 36                     |              |              | (4)            | 32                   |
| IT equipment                                   | 826                    | 575          |              | (61)           | 1,340                |
| Construction in progress                       | 41                     | 90           |              |                | 131                  |
| Others   | 6                      |              |              | (1)            | 5                    |
|  | <b>9,161</b>           | <b>2,426</b> | <b>(130)</b> | <b>(1,544)</b> | <b>9,913</b>         |

| Change:                   | As of January 01, 2025 | Depreciation | As of March 31, 2025 |
|---------------------------|------------------------|--------------|----------------------|
| Right of Use - Leases (i) | 102                    | (17)         | 85                   |
|                           | <b>102</b>             | <b>(17)</b>  | <b>85</b>            |

(i) The right-of-use balance refers to fleet lease agreements.





| Balance breakdown:                             | 03/31/2026    |                          |              | 12/31/2025    |                          |              | Average annual depreciation rates |
|--|---------------|--------------------------|--------------|---------------|--------------------------|--------------|-----------------------------------|
|  | Cost          | Accumulated depreciation | Net          | Cost          | Accumulated depreciation | Net          |                                   |
| Right of Use - Leases                          | 16,814        | (9,964)                  | 6,850        | 15,421        | (8,787)                  | 6,634        | 28.69%                            |
| Buildings and improvements                     | 2,779         | (1,822)                  | 957          | 2,779         | (1,803)                  | 976          | 6.42%                             |
| Machinery, equipment and industrial facilities | 1,510         | (1,255)                  | 255          | 1,511         | (1,246)                  | 265          | 8.76%                             |
| Vehicles, tractors and aircraft                | 526           | (183)                    | 343          | 527           | (150)                    | 377          | 26.40%                            |
| Furniture and fixtures                         | 577           | (545)                    | 32           | 577           | (541)                    | 36           | 8.08%                             |
| IT equipment                                   | 5,676         | (4,336)                  | 1,340        | 5,128         | (4,302)                  | 826          | 19.23%                            |
| Construction in progress                       | 131           |                          | 131          | 41            |                          | 41           |                                   |
| Others   | 260           | (255)                    | 5            | 259           | (253)                    | 6            | 6.67%                             |
|  | <b>28,273</b> | <b>(18,360)</b>          | <b>9,913</b> | <b>26,243</b> | <b>(17,082)</b>          | <b>9,161</b> |                                   |

### (ii) Consolidated

| Change:  | As of January 01, 2026 | Additions    | Foreign exchange variation | Transfers | Write-Offs   | Depreciation   | As of March 31, 2026 |
|--|------------------------|--------------|----------------------------|-----------|--------------|----------------|----------------------|
| Right of Use - Leases (i)                      | 13,429                 | 2,137        | (84)                       |           | (21)         | (2,130)        | 13,331               |
| Land   | 24,985                 |              |                            |           |              |                | 24,985               |
| Buildings and improvements                     | 172,243                |              | (2)                        |           |              | (1,349)        | 170,892              |
| Machinery, equipment and industrial facilities | 112,049                | 404          | (1)                        | 45        |              | (2,955)        | 109,542              |
| Vehicles and tractors                          | 595                    |              | (3)                        |           | (92)         | (60)           | 440                  |
| Furniture and fixtures                         | 4,276                  | 45           | (4)                        |           |              | (192)          | 4,125                |
| IT equipment                                   | 4,892                  | 693          | (8)                        |           |              | (563)          | 5,014                |
| Construction in progress                       | 9,367                  | 1,585        |                            |           |              |                | 10,952               |
| Others   | 1,046                  | 45           |                            | (45)      |              | (42)           | 1,004                |
|  | <b>342,882</b>         | <b>4,909</b> | <b>(102)</b>               | <b>-</b>  | <b>(113)</b> | <b>(7,291)</b> | <b>340,285</b>       |

| Change:  | As of January 01, 2025 | Additions    | Foreign exchange variation | Transfers | Write-Offs   | Depreciation   | As of March 31, 2025 |
|--|------------------------|--------------|----------------------------|-----------|--------------|----------------|----------------------|
| Right of Use - Leases (i)                      | 13,128                 | 166          |                            |           |              | (1,612)        | 11,682               |
| Land   | 24,985                 |              |                            |           |              |                | 24,985               |
| Buildings and improvements                     | 172,289                |              | (2)                        | 64        |              | (1,313)        | 171,038              |
| Machinery, equipment and industrial facilities | 110,053                | 456          | (2)                        | 476       | (45)         | (2,822)        | 108,116              |
| Vehicles and tractors                          | 4,056                  |              | (113)                      |           | (72)         | (414)          | 3,457                |
| Furniture and fixtures                         | 4,549                  | 128          | (6)                        |           |              | (188)          | 4,483                |
| IT equipment                                   | 4,561                  | 1,157        | (8)                        |           |              | (561)          | 5,149                |
| Construction in progress                       | 2,539                  | 3,389        |                            | (540)     |              |                | 5,388                |
| Others   | 1,183                  | (7)          |                            |           |              | (41)           | 1,135                |
|  | <b>337,343</b>         | <b>5,289</b> | <b>(131)</b>               | <b>-</b>  | <b>(117)</b> | <b>(6,951)</b> | <b>335,433</b>       |

(i) The right-of-use balance refers to lease contracts, mainly forklifts and fleets.

| Balance breakdown:                             | 03/31/26       |                          |                | 12/31/25       |                          |                | Average annual depreciation rates |
|--|----------------|--------------------------|----------------|----------------|--------------------------|----------------|-----------------------------------|
|  | Cost           | Accumulated depreciation | Net            | Cost           | Accumulated depreciation | Net            |                                   |
| Right of Use - Leases                          | 27,661         | (14,330)                 | 13,331         | 25,886         | (12,457)                 | 13,429         | 29.58%                            |
| Land   | 24,985         |                          | 24,985         | 24,985         |                          | 24,985         |                                   |
| Buildings and improvements                     | 224,809        | (53,917)                 | 170,892        | 224,813        | (52,570)                 | 172,243        | 2.45%                             |
| Machinery, equipment and industrial facilities | 223,890        | (114,348)                | 109,542        | 223,445        | (111,396)                | 112,049        | 6.51%                             |
| Vehicles, tractors and aircraft                | 1,224          | (784)                    | 440            | 2,785          | (2,190)                  | 595            | 19.73%                            |
| Furniture and fixtures                         | 13,481         | (9,356)                  | 4,125          | 13,445         | (9,169)                  | 4,276          | 9.78%                             |
| IT equipment                                   | 25,306         | (20,292)                 | 5,014          | 24,727         | (19,835)                 | 4,892          | 18.98%                            |
| Construction in progress                       | 10,952         |                          | 10,952         | 9,367          |                          | 9,367          |                                   |
| Others   | 3,921          | (2,917)                  | 1,004          | 3,920          | (2,874)                  | 1,046          | 8.17%                             |
|  | <b>556,229</b> | <b>(215,944)</b>         | <b>340,285</b> | <b>553,373</b> | <b>(210,491)</b>         | <b>342,882</b> |                                   |





In the quarter ended March 31, 2026, loan costs related to construction in progress balances of R\$ 171 (R\$ 145 as of March 31, 2025) were capitalized, referring to balances of works in progress, at an average annual rate of 7.20% (7.74% as of March 31, 2025).

During the quarter, no element was identified that its assets may be recorded at a value exceeding their recoverable amount.

### 12. Intangible assets

#### (i) Parent company

| Change:           | As of January 01, 2026 | Amortization | As of March 31, 2026 |
|-------------------|------------------------|--------------|----------------------|
| Computer software | 500                    | (57)         | 443                  |
|                   | <b>500</b>             | <b>(57)</b>  | <b>443</b>           |

| Balance breakdown: | 03/31/26      |                          |                          |            |             |
|--------------------|---------------|--------------------------|--------------------------|------------|-------------|
|                    | Cost          | Provision for impairment | Accumulated amortization | Net        | Useful life |
| Computer software  | 18,328        | (1,222)                  | (16,663)                 | 443        | 5 years     |
|                    | <b>18,328</b> | <b>(1,222)</b>           | <b>(16,663)</b>          | <b>443</b> |             |

| Balance breakdown: | 12/31/2025    |                          |                          |            |             |
|--------------------|---------------|--------------------------|--------------------------|------------|-------------|
|                    | Cost          | Provision for impairment | Accumulated amortization | Net        | Useful life |
| Computer software  | 18,328        | (1,222)                  | (16,606)                 | 500        | 5 years     |
|                    | <b>18,328</b> | <b>(1,222)</b>           | <b>(16,606)</b>          | <b>500</b> |             |

#### (ii) Consolidated

| Change:                                  | As of January 01, 2026 | Additions    | Foreign exchange variation | Reversal of impairment provision | Write-Offs  | Amortization   | As of March 31, 2026 |
|--|------------------------|--------------|----------------------------|----------------------------------|-------------|----------------|----------------------|
| Goodwill on company acquisition          | 618                    |              |                            |                                  |             |                | 618                  |
| Development and registration of products | 99,889                 | 1,500        | (49)                       | 14                               | (20)        | (2,049)        | 99,285               |
| Computer software                        | 5,329                  |              |                            |                                  |             | (667)          | 4,662                |
|  | <b>105,836</b>         | <b>1,500</b> | <b>(49)</b>                | <b>14</b>                        | <b>(20)</b> | <b>(2,716)</b> | <b>104,565</b>       |

| Change:                                  | As of January 01, 2025 | Additions    | Foreign exchange variation | Provision for impairment | Amortization   | As of March 31, 2025 |
|--|------------------------|--------------|----------------------------|--------------------------|----------------|----------------------|
| Goodwill on company acquisition          | 618                    |              |                            |                          |                | 618                  |
| Development and registration of products | 97,764                 | 5,699        | (62)                       | (641)                    | (1,691)        | 101,069              |
| Computer software                        | 8,363                  | 11           | (1)                        | (11)                     | (780)          | 7,582                |
|  | <b>106,745</b>         | <b>5,710</b> | <b>(63)</b>                | <b>(652)</b>             | <b>(2,471)</b> | <b>109,269</b>       |





| Balance breakdown:                   | 03/31/26       |                          |                          |                | Useful life |
|--------------------------------------|----------------|--------------------------|--------------------------|----------------|-------------|
|                                      | Cost           | Provision for impairment | Accumulated amortization | Net            |             |
| Goodwill on company acquisition      | 618            |                          |                          | 618            | Undefined   |
| Trademarks and licenses purchased    | 2,200          |                          | (2,200)                  |                | 10 years    |
| Product development and registration | 180,812        | (11,802)                 | (69,725)                 | 99,285         | 10 years    |
| Computer software                    | 52,508         | (1,405)                  | (46,441)                 | 4,662          | 5 years     |
| Others                               | 1,333          |                          | (1,333)                  |                | 5 years     |
|                                      | <b>237,471</b> | <b>(13,207)</b>          | <b>(119,699)</b>         | <b>104,565</b> |             |

| Balance breakdown:                   | 12/31/2025     |                          |                          |                | Useful life |
|--------------------------------------|----------------|--------------------------|--------------------------|----------------|-------------|
|                                      | Cost           | Provision for impairment | Accumulated amortization | Net            |             |
| Goodwill on company acquisition      | 618            |                          |                          | 618            | Undefined   |
| Trademarks and licenses purchased    | 2,200          |                          | (2,200)                  |                |             |
| Product development and registration | 179,426        | (11,816)                 | (67,721)                 | 99,889         | 10 years    |
| Computer software                    | 52,508         | (1,405)                  | (45,774)                 | 5,329          | 5 years     |
| Others                               | 1,333          |                          | (1,333)                  |                | 5 years     |
|                                      | <b>236,085</b> | <b>(13,221)</b>          | <b>(117,028)</b>         | <b>105,836</b> |             |

Product development and registration refers to expenses incurred in new veterinary drugs and its amortization is recognized under "Selling costs" (Note 18).

In the quarter ended March 31, 2026, provisions (reversals of provisions) and write-offs representing R\$6 (March 31, 2025 – R\$652) are related to projects that were discontinued or postponed by Management decision.

### 13. Trade accounts payable

|                     | Parent company |               | Consolidated   |               |
|---------------------|----------------|---------------|----------------|---------------|
|                     | 03/31/26       | 12/31/25      | 03/31/26       | 12/31/25      |
| In local currency   | 23,152         | 27,330        | 69,710         | 79,559        |
| In foreign currency | 19,611         | 1,063         | 50,609         | 17,773        |
|                     | <b>42,763</b>  | <b>28,393</b> | <b>120,319</b> | <b>97,332</b> |





### 14. Loans And Financing (Consolidated)

|                        | Financial charges incurred  | Final maturity | 03/31/26       | 12/31/25       |
|------------------------|---|----------------|----------------|----------------|
| In local currency      |   |                |                |                |
| FINEP                  | Weighted average rate of 7.20% p.a.<br>(December 31, 2025 - 7.42% p.a.)   | 2036           | 396,671        | 402,726        |
| BNDES - FINEM          | Weighted average rate of 13.17% p.a.<br>(December 31, 2025 - 12.43% p.a.) | 2032           | 100,384        | 71,748         |
| Working capital (i)    | Average rate of 10.97% p.a.<br>(December 31, 2025 - 10.06% p.a.)          | 2026           | 13,438         | 13,730         |
| Reverse factoring (ii) | Average rate of 18.00% p.a.<br>(December 31, 2025 - 18.92% p.a.)          |                | 1,321          | 1,379          |
|                        |   |                | <b>511,814</b> | <b>489,583</b> |
| Current                |   |                | 57,917         | 52,144         |
| Non-current            |   |                | 453,897        | 437,439        |
|                        |   |                | <b>511,814</b> | <b>489,583</b> |

- (i) Loans and financing obtained by the subsidiary Ouro Fino Colombia S.A.S
- (ii) The Group maintains reverse factoring arrangements with financial institutions, which offer suppliers the option to early receive their receivables. The financial cost of these operations is the responsibility of the suppliers, generating no charges for the Group, and therefore not being considered in the calculation of the average cost of debt.

#### a) Guarantees for loans and financing

Financing for Research, Innovation and Product Development, contracted by subsidiary Ouro Fino Saúde Animal Ltda. with FINEP, is collateralized by: (i) bank-issued guarantees, in the amount of R\$510,658; and (ii) guarantee from the parent company Ouro Fino S.A., under which no charges are levied.

Working capital loans are collateralized by sureties of the parent company and/or controlling shareholders.

The Group does not have any financial instruments, loan or financing agreements, or any other arrangements subject to compliance with financial covenants.

The carrying amounts of loans and financing are close to their fair values.





The breakdown of long-term loans and financing is as follows:

|            | <b>03/31/26</b> | <b>12/31/25</b> |
|------------|-----------------|-----------------|
| 2027       | 64,533          | 59,817          |
| 2028       | 70,533          | 64,319          |
| 2029       | 68,477          | 64,319          |
| 2030       | 62,309          | 56,156          |
| After 2031 | 188,045         | 192,828         |
|            | <b>453,897</b>  | <b>437,439</b>  |

## 15. Provision for legal proceedings

### 15.1 Probable losses

The Group companies are parties to labor, civil and tax litigation in progress, which are being discussed at the administrative and judicial levels, and, where applicable, are supported by judicial deposits. The provision for probable losses arising from these matters is estimated and periodically adjusted by the Executive Board, supported by the opinion of its external legal advisors.

Provisions are as follows:

|       | <b>Parent company</b> |                 | <b>Consolidated</b> |                 |
|-------|-----------------------|-----------------|---------------------|-----------------|
|       | <b>03/31/26</b>       | <b>12/31/25</b> | <b>03/31/26</b>     | <b>12/31/25</b> |
| Tax   |                       |                 | 3,782               | 3,736           |
| Labor | 27                    | 27              | 736                 | 805             |
| Civil |                       |                 |                     | 428             |
|       | <b>27</b>             | <b>27</b>       | <b>4,518</b>        | <b>4,969</b>    |

The net change in the provision for legal proceedings for the quarter is as follows:

|                            | <b>Parent company</b> |                 | <b>Consolidated</b> |                 |
|----------------------------|-----------------------|-----------------|---------------------|-----------------|
|                            | <b>03/31/26</b>       | <b>03/31/26</b> | <b>03/31/26</b>     | <b>03/31/25</b> |
| Opening balance            | 27                    |                 | 4,969               | 6,042           |
| Additions                  |                       |                 | 80                  | 59              |
| Reversals                  |                       |                 | (521)               | (14)            |
| Foreign exchange variation |                       |                 | (10)                | (42)            |
|                            | <b>27</b>             |                 | <b>4,518</b>        | <b>6,045</b>    |





### 15.2 Possible losses

The Group companies are parties to tax, labor and civil lawsuits involving risks of loss classified by the Executive Board as possible, based on the assessment of the legal advisors, for which no provision for estimated possible losses has been recorded.

Possible contingencies are as follows:

|       | Parent company |               |                |                |               |                |
|-------|----------------|---------------|----------------|----------------|---------------|----------------|
|       | 03/31/26       |               |                | 12/31/2025     |               |                |
|       | Administrative | Judicial      | Total          | Administrative | Judicial      | Total          |
| Tax   |                | 5,267         | 5,267          |                | 5,196         | 5,196          |
| Labor |                | 276           | 276            |                | 267           | 267            |
| Civil | 1              | 1,115         | 1,116          | 1              | 496           | 497            |
|       | <b>1</b>       | <b>6,658</b>  | <b>6,659</b>   | <b>1</b>       | <b>5,960</b>  | <b>5,960</b>   |
|       | Consolidated   |               |                |                |               |                |
|       | 03/31/26       |               |                | 12/31/2025     |               |                |
|       | Administrative | Judicial      | Total          | Administrative | Judicial      | Total          |
| Tax   | 80,899         | 17,157        | 98,056         | 79,340         | 16,835        | 96,175         |
| Labor |                | 9,764         | 9,764          |                | 8,262         | 8,262          |
| Civil | 1,105          | 3,111         | 4,216          | 1              | 1,991         | 1,992          |
|       | <b>82,004</b>  | <b>30,032</b> | <b>112,036</b> | <b>79,341</b>  | <b>27,088</b> | <b>106,429</b> |

Tax risks refer mainly to tax assessment notices related to PIS, COFINS, and ICMS. The tax assessment notice related to PIS/COFINS, amounting to R\$72,145 (December 31, 2025 - R\$70,792), was issued by tax authorities against the subsidiary Ouro Fino Saúde Animal Ltda. in May 2019, regarding taxable events that took place in calendar year 2014, and requiring the payment of PIS and COFINS differences calculated under the one-time tax treatment, for not including transactions of Ouro Fino Agronegócio Ltda. and Ouro Fino Pet Ltda. The trial of the case commenced on February 11, 2025, before the CARF. The reporting judge rendered an unfavorable opinion to the Company, however proposing a reduction of the ex officio fine from 150% to 100%. The proceeding was suspended due to a request for review filed by the National Treasury and resumed on October 16, 2025, at which time the panel unanimously ruled unfavorably to the Company. Currently, the Company is awaiting the publication of the decision in order to proceed with its defense, still at the administrative level.

With respect to ICMS, the discussion involves matters related to alleged ICMS credits arising from transactions involving the acquisition of electricity used in the Company's industrial process, subject to the tax substitution regime, in the amount of R\$9,345 (December 31, 2025 - R\$9,158). Furthermore, the Group is involved in other tax proceedings totaling the amount of R\$16,570 (December 31, 2025 - R\$16,241).

### 16. Equity

#### a) Capital

In the quarter ended March 31, 2026, the share capital comprises 53,949,006 common shares (December 31, 2025 - 53,949,006 common shares) all fully subscribed and paid-up and with no par value.





At an Extraordinary General Meeting held on October 29, 2024, the Company's shareholders approved the reduction of the Company's share capital in the total amount of R\$120,134, considering the excess amount, without cancellation of shares, through a cash distribution to shareholders, pursuant to article 173 of the Brazilian Corporations Law ("Capital Reduction"). The Company emphasizes that the approved Capital Reduction is aligned with its value creation strategy for all shareholders, without compromising its growth or investment capacity. The payment was made on January 31, 2025.

b) Allocation of profit

According to the bylaws, profit will be allocated as follows:

- 5% to the legal reserve, limited to 20% of share capital.
- Minimum dividend of 25% of profit adjusted according to Article 202 of Law 6.404.
- The remaining balance will be distributed as approved at a Shareholders' Meeting by shareholders representing at least 2/3 (two thirds) of the voting shares, in compliance with the applicable legal provisions.

c) Equity valuation adjustments

These relate to the effect from adoption of the deemed cost method to record land in subsidiaries from January 1, 2009, as well as to all foreign exchange rate differences resulting from the translation of the balance sheet and profit or loss of subsidiaries abroad.

d) Share-Based Compensation Plan - Long-Term Incentive

At the Extraordinary Shareholder's Meeting held on January 29, 2021, the shareholders approved the Long-Term Share-Based Incentive Plan ("ILP Plan") of the Company.

ILP Plan aims to allow eligible persons, subject to certain conditions established in the Programs, to receive Shares with the purpose of: (i) stimulating the Company's social purpose expansion, (ii) aligning the interests of eligible persons to those of Company's shareholders, (iii) encourage the value creation for the Company and (iv) share risks and gains equitably among shareholders, managers and employees.

ILP Plan is managed by the Board of Directors and the Share-based compensation will be made through the signing of ILP agreements, which shall specify the base number of shares, terms and conditions for the transfer of shares by the Company to the beneficiaries, final term for receiving Share-based compensation, share price and payment conditions.

General Characteristics of ILP Plan

ILP Plan features: (i) "Performance Shares granted" from 2021, with a forecast for 5 grants until 2025; (ii) grants made annually following market practices; (iii) 3-year vesting period, with performance goals measured at the end of the grace period; (iv) performance indicators and performance goals defined in each grant; and (v) termination rules following good market practices.

ILP Plan will be settled through treasury shares, being treated as compensation (charges via payroll), but with the possibility of settlement in cash and commitment of up to 2% of the Company's Capital.





The Programs' Performance goals are linked to Net Income and the Performance of the Company's Shares, with 60% weight for Net Income and 40% weight for the appreciation of Shares.

The measurement for Net Income will be assessed based on the compound profit, that is, 3 years together, with margin for variations up or down during the period, having an adjusted starting number of the net income of the year prior to the grant considering the goals set by the Executive Board.

For the measurement of the starting share price, the average value weighted by the trading volume of the last 30 trading sessions prior to the end date of the vesting period will be considered (the amount will be adjusted by the payment of dividends in the quarter using the concept of Total Shareholder Return).

The fair value of these shares was calculated using the Monte Carlo simulation, which takes into account the historical share volatility and the acceleration/penalty curve for the quantity delivered as a result of performance.

In the quarter ended March 31, 2025, upon completion of the vesting period, the Group's Executive Board evaluated the performance indicators established in the Plan and concluded that the stipulated targets were not met. As a result, the full reversal of the provision recognized during the vesting period, including INSS and FGTS charges, in the amount of R\$1,358, was recognized in the statement of profit or loss.

## 17. Revenues

The reconciliation between gross sales and net revenue is as follows:

|                               | Parent company        | Consolidated          |                       |
|-------------------------------|-----------------------|-----------------------|-----------------------|
|                               | 03/31/26              | 03/31/26              | 03/31/25              |
| In Brazil:                    |                       |                       |                       |
| Gross sales and services      | 251,464               | 252,115               | 183,436               |
| Taxes and deductions on sales | (23,090)              | (30,545)              | (21,381)              |
|                               | <u>228,374</u>        | <u>221,570</u>        | <u>162,055</u>        |
| Abroad:                       |                       |                       |                       |
| Gross sales                   |                       | 29,325                | 27,838                |
| Taxes and deductions on sales |                       | (426)                 | (327)                 |
|                               | <u>-</u>              | <u>28,899</u>         | <u>27,511</u>         |
|                               | <b><u>228,374</u></b> | <b><u>250,469</u></b> | <b><u>189,566</u></b> |

The Parent Company's net revenue began to reflect sales operations as of October 1, 2025, the date on which the subsidiary Ouro Fino Agronegócio Ltda. was merged into the Parent, as described in Note 1.

Consolidated net revenue by operating segment is disclosed in Note 27.





### 18. Costs and Expenses by nature

|   | Parent company |              | Consolidated   |                |
|---|----------------|--------------|----------------|----------------|
|   | 03/31/26       | 03/31/25     | 03/31/26       | 03/31/25       |
| Cost of sales (i)                         |                |              |                |                |
| Variable costs (materiais and supplies)   |                |              | 53,290         | 50,415         |
| Distribution Products (Resale)            | 136,869        |              | 28,255         | 8,900          |
| Personnel expenses                        |                |              | 15,724         | 17,831         |
| Outsourced services                       |                |              | 6,053          | 6,989          |
| Depreciation and amortization             |                |              | 6,481          | 6,109          |
| Electricity                               |                |              | 2,305          | 3,357          |
| Provision (reversal) for inventory losses | 2,293          |              | 1,254          | 1,560          |
| Others                                    |                |              | 2,165          | 2,549          |
|   | <b>139,162</b> |              | <b>115,527</b> | <b>97,710</b>  |
| Selling expenses                          |                |              |                |                |
| Personnel expenses                        | 23,331         |              | 29,596         | 26,528         |
| Sales team expenses                       | 13,404         |              | 16,119         | 11,732         |
| Freight expenses                          | 5,975          |              | 8,921          | 6,592          |
| Outsourced services                       | 4,446          |              | 5,863          | 5,073          |
| Depreciation and amortization             | 1,533          |              | 1,967          | 1,775          |
| Telecommunication and energy              | 56             |              | 97             | 104            |
| Provision for inventory losses            | (134)          |              | (134)          |                |
| Others                                    | 1,300          |              | 1,465          | 1,445          |
|   | <b>49,911</b>  |              | <b>63,894</b>  | <b>53,249</b>  |
| Expenses on research and innovation       |                |              |                |                |
| Personnel expenses                        |                |              | 5,907          | 4,363          |
| Outsourced services                       |                |              | 10,233         | 6,173          |
| Depreciation and amortization             |                |              | 774            | 710            |
| Telecommunication and energy              |                |              | 32             | 39             |
| Provision for inventory losses            |                |              | 147            |                |
| Others                                    |                |              | 1,336          | 1,743          |
|   |                |              | <b>18,429</b>  | <b>13,028</b>  |
| General and administrative expenses       |                |              |                |                |
| Personnel expenses                        | 3,909          | 2,517        | 12,256         | 10,174         |
| Outsourced services                       | 3,195          | 352          | 2,652          | 3,443          |
| Depreciation and amortization             | 64             | 17           | 785            | 828            |
| Travel expenses                           | 59             | 84           | 178            | 172            |
| Telecommunication and energy              | 15             |              | 62             | 135            |
| Expenses with vehicles                    | 21             | 23           | 39             | 184            |
| Donations and sponsorships                |                |              | 32             | 12             |
| Other                                     | 190            | 40           | 785            | 920            |
|   | <b>7,453</b>   | <b>3,033</b> | <b>16,789</b>  | <b>15,868</b>  |
|   | <b>196,526</b> | <b>3,033</b> | <b>214,639</b> | <b>179,855</b> |

As of October 1, 2025, following the merger of Ouro Fino Agronegócio Ltda., the Parent Company began recognizing amounts in cost of goods sold and selling expenses, as detailed in Note 1.

(i) The change in "cost of sales" in the quarter also refers to the result of the variables of volume sold between the quarters.





### 19. Other revenues (expenses), net

|   | Parent company |          | Consolidated   |                |
|---|----------------|----------|----------------|----------------|
|   | 03/31/26       | 03/31/25 | 03/31/26       | 03/31/25       |
| Gain on disposal and write-off of PP&E              | 5              |          | 81             | 116            |
| Provision for impairment of intangible assets (i)   |                |          | 14             | (652)          |
| Gain (loss) on disposal of intangible assets (i)    |                |          | (20)           | 333            |
| Federal, state, municipal taxes and fees            | (16)           | (8)      | (257)          | (137)          |
| Gains (losses) on sales of scrap, rentals and other | (731)          | 47       | (625)          | (489)          |
| Other losses  | (517)          | (37)     | (461)          | (310)          |
|   | <b>(1,259)</b> | <b>2</b> | <b>(1,268)</b> | <b>(1,139)</b> |

(i) Refer to provisions and write-offs of projects discontinued or postponed by Management decision (Note 12).

### 20. Financial result

|   | Parent company |              | Consolidated    |                |
|---|----------------|--------------|-----------------|----------------|
|   | 03/31/26       | 03/31/25     | 03/31/26        | 03/31/25       |
| Financial income:                                 |                |              |                 |                |
| Revenue from financial investments                | 3,464          | 1,013        | 8,674           | 3,896          |
| Inflation adjustment                              | 1,071          | 8            | 1,077           | 26             |
| Interest received                                 | 160            |              | 298             | 161            |
| Other   | 2              | 2            | 2               | 22             |
|   | <b>4,697</b>   | <b>1,023</b> | <b>10,051</b>   | <b>4,105</b>   |
| Financial expenses:                               |                |              |                 |                |
| Interest paid                                     | (353)          | (5)          | (9,463)         | (7,244)        |
| Finance charges                                   | (31)           |              | (1,531)         | (511)          |
| Other   | (84)           | (18)         | (178)           | (146)          |
|   | <b>(468)</b>   | <b>(23)</b>  | <b>(11,172)</b> | <b>(7,901)</b> |
| Derivative financial instruments, net:            |                |              |                 |                |
| Gains on derivatives (foreign exchange variation) |                |              | 771             | 114            |
|   |                |              | <b>771</b>      | <b>114</b>     |
| Foreign exchange variation, net                   | 36             |              | (982)           | (302)          |
| <b>Financial result</b>                           | <b>4,265</b>   | <b>1,000</b> | <b>(1,332)</b>  | <b>(3,984)</b> |

### 21. Income Tax And Social Contribution Expense

The Company and its subsidiary Ouro Fino Saúde Animal Ltda. calculate income tax and social contribution under the "Taxable Income" method, at the rates of 25% for income tax and 9% for social contribution. The subsidiaries located in Mexico and Colombia calculate their taxes based on the respective local regulations. Therefore, there is no direct correlation between the amounts presented in the consolidated statement of profit or loss and those that would have been obtained by applying the aforementioned standard rates.





The income tax and social contribution expense is reconciled to the standard rates as shown below:

|  | Parent company  |              | Consolidated    |                |
|--|-----------------|--------------|-----------------|----------------|
|  | 03/31/26        | 03/31/25     | 03/31/26        | 03/31/25       |
| Earnings before income tax and social contribution   | 33,205          | 2,049        | 33,230          | 4,588          |
| Statutory tax rates  | 34%             | 34%          | 34%             | 34%            |
|  | <b>(11,290)</b> | <b>(696)</b> | <b>(11,298)</b> | <b>(1,560)</b> |
| <u>Reconciliation for effective tax:</u>   |                 |              |                 |                |
| <b>Income Tax and Social Contribution</b>  |                 |              |                 |                |
| <b>Regarding the following permanent differences:</b>  |                 |              |                 |                |
| Equity in the results of investees   | (561)           | 1,387        |                 |                |
| Calculation adjustments on subsidiary taxed under presumptive income regime                              |                 |              |                 | 6              |
| Calculation adjustments on subsidiaries abroad taxed at the rate in effect in their respective countries |                 |              | (797)           | 28             |
| Unrecognized deferred taxes  |                 | (690)        |                 | (690)          |
| Other  | 4               | (1)          | 222             | (324)          |
| <b>Income tax and social contribution</b>  | <b>(11,847)</b> |              | <b>(11,873)</b> | <b>(2,540)</b> |
| Reconciliation with the statement of profit or loss  |                 |              |                 |                |
| Current  | (6,061)         |              | (7,679)         | (2,398)        |
| Deferred   | (5,786)         |              | (4,194)         | (142)          |
|  | <b>(11,847)</b> |              | <b>(11,873)</b> | <b>(2,540)</b> |
| <b>Effective rate</b>  | <b>-35.68%</b>  | <b>0.00%</b> | <b>-35.73%</b>  | <b>-55.36%</b> |

## 22. Basic and diluted earnings per share

Basic and diluted earnings per share are calculated by dividing the earnings attributable to the Company's shareholders by the weighted average number of common shares outstanding during the quarter.

|  | 03/31/26       | 03/31/25       |
|--|----------------|----------------|
| Net income for the quarter attributable to the Company's shareholders                        | 21,358         | 2,049          |
| Weighted average number of common shares outstanding in the quarter (in thousands of shares) | 53,768         | 53,768         |
| <b>Basic and diluted earnings per share</b>  | <b>0.39723</b> | <b>0.03811</b> |

The Company has no outstanding common shares that could cause dilution or convertible debt into common shares. Thus, basic and diluted earnings per share are equivalent.



**23. Employee benefits**

## a) Private pension plan - defined contribution

The Group companies sponsor a defined contribution pension plan for their employees. The plan is managed by Brasilprev Seguros e Previdência S.A. Company contributions to the plan in the quarter ended March 31, 2026 amounted to R\$ 354 (March 31, 2025 R\$ 265).

## b) Short-term incentives

The Group offers a short-term incentive program ("ICP") to its employees, calculated based on quantitative and qualitative goals established by the Executive Board. For the quarter ended March 31, 2026, the impact of the short-term incentive was R\$ 4,124 (R\$ 3,443 as of March 31, 2025).

c) Long-term Incentive Plan – "*Phantom Units*"

At the Extraordinary Shareholders' Meeting held on September 23, 2022, the shareholders approved the creation of the new Grant Program under the Long-Term Incentive Plan and, subsequently, on the minutes of the Board of Directors meeting held on October 19, 2022, the Long-Term Incentive Plan ("*Phantom Units*") was approved, replacing the Restricted Share-Based Compensation Plan ("RSU").

The purpose of *Phantom Units* is to incentivize Eligible Persons, aiming to: (i) encourage the expansion of the Company's corporate goals, (ii) align the interests of Eligible Persons with those of the Company's shareholders, (iii) enable the Company to attract and retain Eligible Persons, (iv) foster the creation of value to the Company and (v) share long-term risks and gains, indirectly, by means of the Shares upside, on an equal basis between shareholders and Eligible Persons.

## General Characteristics of the Plan

Each beneficiary will be entitled to receive, in Brazilian currency, the higher of: (i) the Share price at B3 on the last day of the vesting period, or (ii) the result of EBITDA multiples, and the vesting period ranges from 3 to 7 years.

The Plan will be settled in cash and its fair value will be measured at the end of each period.

The Plan's fair value is measured based on the share price (closing) or EBITDA multiples. For the quarter ended March 31, 2026, the plan was calculated based on EBITDA multiples and, therefore, the Group recognized expenses, including INSS and FGTS charges, in the amount of R\$ 2,725 (March 31, 2025 - 2,715).





### 24. Related-Party Balances And Transactions

#### a) Balances and main transactions

|   | Parent company |                | Consolidated  |               |
|---|----------------|----------------|---------------|---------------|
|   | 03/31/26       | 12/31/25       | 03/31/26      | 12/31/25      |
| <b>Current assets:</b>                    |                |                |               |               |
| Interest on equity receivable             |                |                |               |               |
| Ouro Fino Saúde Animal Ltda.              |                | 9,350          |               |               |
| Other assets (i)                          |                |                |               |               |
| Ouro Fino Saúde Animal Ltda.              | 187            | 210            |               |               |
| Condomínio Rural Ouro Fino                | 20             | 6              | 78            | 98            |
| Ouro Fino Química Ltda.                   | 133            | 83             | 133           | 84            |
|   | <b>340</b>     | <b>9,649</b>   | <b>211</b>    | <b>182</b>    |
| <b>Current liabilities:</b>               |                |                |               |               |
| Dividends and interest on equity payables |                |                |               |               |
| Shareholders                              | 52,799         | 52,799         | 52,799        | 52,799        |
| Trade account payable (ii)                |                |                |               |               |
| Ouro Fino Saúde Animal Ltda.              | 115,705        | 136,864        |               |               |
| Ouro Fino Hong Kong Limited.              |                |                | 6,295         | 2,072         |
| Other liabilities (i)                     |                |                |               |               |
| Ouro Fino Saúde Animal Ltda.              | 2,402          | 2,353          |               |               |
| Condomínio Rural Ouro Fino                |                |                | 17            |               |
| Neotech Soluções Ambientais Ltda.         |                |                | 8             | 50            |
| Ouro Fino Química Ltda.                   |                | 28             | 222           | 31            |
|   | <b>170,906</b> | <b>192,044</b> | <b>59,341</b> | <b>54,952</b> |

|  | Parent company   |             | Consolidated   |                |
|--|------------------|-------------|----------------|----------------|
|  | 03/31/26         | 03/31/25    | 03/31/26       | 03/31/25       |
| <b>Main transactions:</b>                      |                  |             |                |                |
| Purchase of products for resale (ii)           |                  |             |                |                |
| Ouro Fino Saúde Animal Ltda.                   | (124,187)        |             |                |                |
| Purchase of raw materials (ii)                 |                  |             |                |                |
| Ouro Fino Hong Kong Limited.                   |                  |             | (6,599)        |                |
| Product sales revenue                          |                  |             |                |                |
| Condomínio Rural Ouro Fino                     | 27               |             | 27             | 67             |
| Ouro Fino Química Ltda.                        |                  |             | 1              |                |
| Shared Services Center (CSC) reimbursement (i) |                  |             |                |                |
| Ouro Fino Saúde Animal Ltda.                   | (2,708)          | (107)       |                |                |
| Ouro Fino Agronegócio Ltda.                    |                  | 58          |                |                |
| Royalties                                      |                  |             |                |                |
| Condomínio Rural Ouro Fino                     |                  |             |                | 1              |
| Ouro Fino Química Ltda.                        | 50               | 50          | 50             | 50             |
| Expenses on rentals and condominia             |                  |             |                |                |
| Condomínio Rural Ouro Fino                     |                  |             | (886)          | (1,255)        |
| Other expenses, net                            |                  |             |                |                |
| Ouro Fino Saúde Animal Ltda.                   | (2,513)          | (37)        |                |                |
| Ouro Fino Química Ltda.                        |                  | (6)         | (222)          | (760)          |
| Incineration services                          |                  |             |                |                |
| Neotech Soluções Ambientais Ltda.              |                  |             | (76)           | (175)          |
|  | <b>(129,331)</b> | <b>(42)</b> | <b>(7,705)</b> | <b>(2,072)</b> |





## (i) Other assets and liabilities

Other assets and liabilities are represented by the reimbursement of expenses, especially those incurred with the Shared Services Center ("CSC"), under the expense sharing agreement entered into on September 30, 2014.

## (ii) Trade accounts payable

The Company and its subsidiaries carry out commercial transactions with companies within the same economic group, primarily between the Parent Company and the subsidiary Ouro Fino Saúde Animal Ltda., involving the purchase and sale of finished products for distribution. The transactions are conducted at prices and terms consistent with those applied in transactions with independent third parties.

## b) Management compensation

Key management personnel include the members of the Board of Directors and the officers appointed pursuant to the Company's bylaws whose compensation is approved at the Annual Shareholders' Meeting. The compensation paid or payable to key management personnel for their services is described below:

|                              | <b>03/31/26</b> | <b>03/31/25</b> |
|------------------------------|-----------------|-----------------|
| Long-term incentives         | 2,066           | 901             |
| Salaries                     | 1,067           | 880             |
| Variable compensation        | 340             | 679             |
| Labor charges                | 521             | 225             |
| Direct and indirect benefits | 47              | 59              |
|                              | <b>4,041</b>    | <b>2,744</b>    |




**25. Other Disclosures On Cash Flows (Consolidated)**

|  | Loans and financing | Cash and cash equivalents | Debt Net       |
|--|---------------------|---------------------------|----------------|
| <b>Balance as of January 01, 2026</b>    | <b>489,583</b>      | <b>(250,821)</b>          | <b>238,762</b> |
| Raising of funds                         | 29,992              |                           | 29,992         |
| Repayment of principal                   | (8,981)             |                           | (8,981)        |
| Payment of interest                      | (7,394)             |                           | (7,394)        |
| Reverse factoring                        | (58)                |                           | (58)           |
| Increase in cash and cash equivalents    |                     | (150,453)                 | (150,453)      |
| Non-cash changes                         | 13,559              | (150,453)                 | (136,894)      |
| Capitalized interest                     | 208                 |                           | 208            |
| Foreign exchange variations and interest | 8,464               | 171                       | 8,635          |
| Non-cash changes                         | 8,672               | 171                       | 8,843          |
| <b>Balance as of March 31, 2026</b>      | <b>511,814</b>      | <b>(401,103)</b>          | <b>110,711</b> |
| <b>Balance as of January 01, 2025</b>    | <b>359,354</b>      | <b>(233,957)</b>          | <b>125,397</b> |
| Raising of funds                         |                     |                           |                |
| Repayment of principal                   | (10,622)            |                           | (10,622)       |
| Payment of interest                      | (5,469)             |                           | (5,469)        |
| Reverse factoring                        | (1,323)             |                           | (1,323)        |
| Decrease in cash and cash equivalents    |                     | 85,243                    | 85,243         |
| Non-cash changes                         | (17,414)            | 85,243                    | 67,829         |
| Capitalized interest                     | 142                 |                           | 142            |
| Foreign exchange variations and interest | 6,134               | 212                       | 6,346          |
| Non-cash changes                         | 6,276               | 212                       | 6,488          |
| <b>Balance as of March 31, 2025</b>      | <b>348,216</b>      | <b>(148,502)</b>          | <b>199,714</b> |





## 26. Financial Instruments

### 26.1 Financial instruments by category

|                                       | Parent company |                | Consolidado    |                |
|---------------------------------------|----------------|----------------|----------------|----------------|
|                                       | 03/31/26       | 12/31/25       | 03/31/26       | 12/31/25       |
|                                       | Amortized cost | Amortized cost | Amortized cost | Amortized cost |
| Assets as per balance sheet           |                |                |                |                |
| Cash and cash equivalents             | 204,768        | 69,354         | 401,103        | 250,821        |
| Trade receivables                     | 287,797        | 379,822        | 316,532        | 430,367        |
| Related parties                       | 340            | 9,649          | 211            | 182            |
| Other assets, except prepaid expenses | 1,166          | 6,454          | 2,962          | 9,191          |
|                                       | <b>494,071</b> | <b>465,279</b> | <b>720,808</b> | <b>690,561</b> |

|                                   | Parent company |                | Consolidated  |                |   |                |
|-----------------------------------|----------------|----------------|---|----------------|---|----------------|
|                                   | 03/31/26       | 12/31/25       | 03/31/26  |                | 12/31/25  |                |
|                                   | Amortized cost | Amortized cost | Liabilities measured at fair value through profit or loss | Amortized cost | Liabilities measured at fair value through profit or loss | Amortized cost |
| Liabilities as per balance sheet: |                |                |   |                |   |                |
| Trade accounts payable            | 42,763         | 28,393         |   | 120,319        |   | 97,332         |
| Derivative financial instruments  |                |                | 268   |                | 597   |                |
| Loans and financing               |                |                |   | 511,814        |   | 489,583        |
| Related parties                   | 118,107        | 139,245        |   | 6,542          |   | 2,153          |
| Leases                            | 8,075          | 7,947          |   | 14,234         |   | 14,005         |
| Other liabilities                 | 18,224         | 17,920         |   | 48,979         |   | 44,852         |
|                                   | <b>187,169</b> | <b>193,505</b> | <b>268</b>  | <b>701,888</b> | <b>597</b>  | <b>647,925</b> |

### 26.2 Financial risk management

The Group has exposure to the following risks arising from financial instruments:

- Market risks;
- Credit risks; and
- Liquidity risk.

#### Risk management framework

The Board of Directors is responsible for establishing and overseeing the Group's risk management structure. The Executive Board, in turn, is responsible for developing and monitoring the risk management policies and regularly reporting its activities to the Board.

The Group's risk management policies are designed to identify and analyze the risks to which the Group is exposed, to establish appropriate risk limits and controls, and to monitor risks and compliance with the defined limits. The risk management policies and systems are reviewed regularly to reflect changes in market conditions and in the Group's activities. Through its policies, training programs, and





management procedures, the Group seeks to maintain a disciplined and controlled environment in which all employees are aware of their responsibilities and obligations.

The Group companies' activities expose them to financial risks, mainly related to foreign exchange variations, fluctuations in interest rates, credit and liquidity risks. The objective of risk management is to reduce potential unexpected variations in the results arising from the aforementioned risks. The Group's Executive Board manages its financial risks as the basis for its growth strategy and satisfactory cash flows. The Group has a Finance Committee that establishes management strategies regarding such exposures, which may include the utilization of derivative or non-derivative financial instruments for hedging potential risks.

The Group monitors the levels of exposure to each market risk (foreign exchange variation and interest rate) through an analysis based on accounting exposure and future cash flow projections.

### a) Market risks

#### (i) Foreign exchange risk

This risk arises from the possibility of the Group incurring unexpected losses due to fluctuations in foreign exchange rates which reduce the amount of assets and increase liabilities. The Group is mainly exposed to fluctuation in the U.S. dollar exchange rate.

Where necessary, in order to hedge against foreign exchange risks, derivative transactions are used, mainly swaps and NDF (non-deliverable forward) contracts.

Swaps are classified as derivatives at fair value through profit or loss and are entered into to exchange the charges on loans and financing initially obtained in foreign currency for charges based on the Interbank Deposit Certificate (CDI) rate.

NDFs are classified as derivatives at fair value through profit or loss and were contracted to mitigate possible foreign exchange gains or losses that may be incurred by the Group.

Gains and losses are recognized within "Financial Result" in the statement of profit or loss.

The following table presents the consolidated accounting balances of assets and liabilities, substantially, denominated in U.S. dollars:

|  | Parent company  |                | Consolidated    |               |
|--|-----------------|----------------|-----------------|---------------|
|  | 03/31/26        | 12/31/25       | 03/31/26        | 12/31/25      |
| Assets in foreign currency                 |                 |                |                 |               |
| Cash and cash equivalents (Note 5)         | 43              |                | 14,977          | 6,648         |
| Trade accounts receivable (Note 6)         |                 |                | 13,185          | 26,809        |
|  | 43              | -              | 28,162          | 33,457        |
| Liabilities in foreign currency            |                 |                |                 |               |
| Related parties (Note 24)                  |                 |                | (6,295)         | (2,072)       |
| Trade accounts payable (Note 13)           | (19,611)        | (1,063)        | (50,609)        | (17,773)      |
|  | (19,611)        | (1,063)        | (56,904)        | (19,845)      |
| <b>Net exposure - assets (liabilities)</b> | <b>(19,568)</b> | <b>(1,063)</b> | <b>(28,742)</b> | <b>13,612</b> |





Assets and liabilities denominated in foreign currency are regularly monitored through projected cash inflows and outflows related to foreign exchange assets and liabilities. The amount of assets and liabilities in foreign currency fluctuates throughout the year, which may or may not give rise to a mismatch. Consequently, in order to mitigate risks arising from any possible foreign exchange exposure, whenever required, derivative transactions may be entered into.

The table below presents two scenarios, considering the changes in the quotations of the Brazilian real (R\$) against the U.S. dollar (US\$).

|                           |                   | Parent company         |   |                                   |                                   |
|---------------------------|-------------------|------------------------|---|-----------------------------------|-----------------------------------|
| Assets/liabilities        | Risk              | Balance as of 03/31/26 | Impact                                  |                                   |                                   |
|                           |                   |                        | Likely scenario (*) (US\$ 1 = R\$ 5.37) | Scenario 2 (US\$ variation - 25%) | Scenario 3 (US\$ variation - 50%) |
| Cash and cash equivalents | US\$ depreciation | 43                     | 1                                       | (11)                              | (22)                              |
| Trade accounts payable    | US\$ appreciation | (19,611)               | (587)                                   | (5,049)                           | (10,099)                          |
|                           |                   | <b>(19,568)</b>        | <b>(586)</b>                            | <b>(5,060)</b>                    | <b>(10,121)</b>                   |

  

|                        |                   | Parent company         |   |                                   |                                   |
|------------------------|-------------------|------------------------|---|-----------------------------------|-----------------------------------|
| Assets/liabilities     | Risk              | Balance as of 12/31/25 | Impact                                  |                                   |                                   |
|                        |                   |                        | Likely scenario (*) (US\$ 1 = R\$ 5.65) | Scenario 2 (US\$ variation - 25%) | Scenario 3 (US\$ variation - 50%) |
| Trade accounts payable | US\$ appreciation | (1,063)                | (29)                                    | (273)                             | (546)                             |
|                        |                   | <b>(1,063)</b>         | <b>(29)</b>                             | <b>(273)</b>                      | <b>(546)</b>                      |

  

|                           |                   | Consolidated           |   |                                   |                                   |
|---------------------------|-------------------|------------------------|---|-----------------------------------|-----------------------------------|
| Assets/liabilities        | Risk              | Balance as of 03/31/26 | Impact                                  |                                   |                                   |
|                           |                   |                        | Likely scenario (*) (US\$ 1 = R\$ 5.37) | Scenario 2 (US\$ variation - 25%) | Scenario 3 (US\$ variation - 50%) |
| Cash and cash equivalents | US\$ depreciation | 14,977                 | 448                                     | (3,856)                           | (7,713)                           |
| Trade accounts receivable | US\$ depreciation | 13,185                 | 395                                     | (3,395)                           | (6,790)                           |
| Related parties           | US\$ appreciation | (6,295)                | (188)                                   | (1,621)                           | (3,242)                           |
| Trade accounts payable    | US\$ appreciation | (50,609)               | (1,515)                                 | (13,031)                          | (26,062)                          |
|                           |                   | <b>(28,742)</b>        | <b>(860)</b>                            | <b>(21,903)</b>                   | <b>(43,807)</b>                   |

  

|                           |                   | Consolidated           |   |                                   |                                   |
|---------------------------|-------------------|------------------------|---|-----------------------------------|-----------------------------------|
| Assets/liabilities        | Risk              | Balance as of 12/31/25 | Impact                                  |                                   |                                   |
|                           |                   |                        | Likely scenario (*) (US\$ 1 = R\$ 5.65) | Scenario 2 (US\$ variation - 25%) | Scenario 3 (US\$ variation - 50%) |
| Cash and cash equivalents | US\$ depreciation | 6,648                  | 179                                     | (1,707)                           | (3,414)                           |
| Trade accounts receivable | US\$ depreciation | 26,809                 | 722                                     | (6,883)                           | (13,766)                          |
| Related parties           | US\$ appreciation | (2,072)                | (56)                                    | (532)                             | (1,064)                           |
| Trade accounts payable    | US\$ appreciation | (17,773)               | (479)                                   | (4,563)                           | (9,126)                           |
|                           |                   | <b>13,612</b>          | <b>367</b>                              | <b>(13,684)</b>                   | <b>(27,369)</b>                   |

(\*) The expected rate for the US Dollar is US\$1=5.37 (December 31, 2025 - US\$1=5.65)  
 (Source: <https://www3.bcb.gov.br/expectativas2/#/consultaSeriesEstatisticas>)

### (ii) Interest rate risk

This risk arises from the possibility that the Group may incur losses due to adverse fluctuations in interest rates. As its interest rate risk primarily arises from loans and financing, the Group seeks to maintain a stable relation between short- and long-term debts. Financial investments are linked to the CDI rate.





The Group's Executive Board continuously monitors market interest rates in order to assess the need to enter into new derivative transactions to hedge against the volatility risk of these rates.

Currently, 100% of the Group's financing transactions are carried out at floating interest rates (December 31, 2025 - 100% at floating rates). The value of floating rate transactions may cause volatility in the average cost of transactions due to the hike, mainly, of TR, TJLP, SELIC and IPC-A and its impact on CDI, and, aiming to minimize this impact, the Group's Executive Board contracts, as necessary, an interest rate hedge transaction, whereby the result for the Company is a cost in percentage of CDI. The risk of fluctuations in the indexes of these transactions is partially mitigated by the volume of funds held in cash.

The table below presents three scenarios, considering the percentage variations in the average cost of debt operations.

| Agreements        | Index | Balance as of 03/31/26 | Current scenario | Scenario <sup>1</sup> (+1 p.p) | Scenario <sup>2</sup> (+2 p.p) | Scenario <sup>3</sup> (+3 p.p) | Impact                       |                              |                              |
|-------------------|-------|------------------------|------------------|--------------------------------|--------------------------------|--------------------------------|------------------------------|------------------------------|------------------------------|
|                   |       |                        |                  |                                |                                |                                | Scenario <sup>1</sup> +1 p.p | Scenario <sup>2</sup> +2 p.p | Scenario <sup>3</sup> +3 p.p |
| BNDES             | IPCA  | 100,384                | 13.17%           | 14.17%                         | 15.17%                         | 16.17%                         | (163)                        | (223)                        | (281)                        |
| Working Capital   | IBR   | 13,438                 | 10.97%           | 11.97%                         | 12.97%                         | 13.97%                         | (18)                         | (29)                         | (40)                         |
| FINEP             | TJLP  | 171,258                | 10.55%           | 11.55%                         | 12.55%                         | 13.55%                         | (292)                        | (361)                        | (431)                        |
| FINEP             | TR    | 225,413                | 5.11%            | 6.11%                          | 7.11%                          | 8.11%                          | (168)                        | (259)                        | (349)                        |
| Reverse factoring | PRE   | 1,321                  | 18.00%           |                                |                                |                                |                              |                              |                              |
| <b>511,814</b>    |       |                        |                  |                                |                                |                                | <b>(641)</b>                 | <b>(872)</b>                 | <b>(1,101)</b>               |

  

| Agreements        | Index | Balance as of 12/31/25 | Current scenario | Scenario <sup>1</sup> (+1 p.p) | Scenario <sup>2</sup> (+2 p.p) | Scenario <sup>3</sup> (+3 p.p) | Impact                       |                              |                              |
|-------------------|-------|------------------------|------------------|--------------------------------|--------------------------------|--------------------------------|------------------------------|------------------------------|------------------------------|
|                   |       |                        |                  |                                |                                |                                | Scenario <sup>1</sup> +1 p.p | Scenario <sup>2</sup> +2 p.p | Scenario <sup>3</sup> +3 p.p |
| BNDES             | IPCA  | 71,748                 | 12.43%           | 13.43%                         | 14.43%                         | 15.43%                         | (91)                         | (143)                        | (220)                        |
| Working Capital   | IBR   | 13,730                 | 10.06%           | 11.06%                         | 12.06%                         | 13.06%                         | (22)                         | (42)                         | (86)                         |
| FINEP             | TJLP  | 177,264                | 10.34%           | 11.34%                         | 12.34%                         | 13.34%                         | (286)                        | (418)                        | (613)                        |
| FINEP             | TR    | 225,462                | 5.55%            | 6.55%                          | 7.55%                          | 8.55%                          | (133)                        | (308)                        | (565)                        |
| Reverse factoring | PRE   | 1,379                  | 18.92%           |                                |                                |                                |                              |                              |                              |
| <b>489,583</b>    |       |                        |                  |                                |                                |                                | <b>(532)</b>                 | <b>(912)</b>                 | <b>(1,483)</b>               |

b) Credit risks

The Group is potentially subject to credit risk related to trade receivables, financial investments and derivatives.

To limit the risk associated with financial assets, especially financial investments and derivative contracts, the Group's Executive Board opts for first-class financial institutions, and therefore, current account balances and financial investments in the amount of R\$401,026 (December 31 2025 – R\$ 250,732) are maintained in financial institutions considered "tier-1", with the majority of banks classified as (BB) by Standard & Poor's.

Trade account receivables-related credit risk is mitigated through a broad customer base and careful selection of customers by business segment (production animals, companion animals, and international operations), in addition to the utilization of guarantees, establishment of individual exposure limits and a well-defined credit policy that utilizes credit risk modeling, through which a credit rating is assigned to each customer, based on the Group's experience in the market.

The Group's Executive Board classifies its customers' portfolio through risk evaluation methodologies developed internally, with the purpose of properly assessing the real risk of its customers. Weights are assigned to each variable,





such as the history of payments, length of the business relationship with the Group, how long the company has been operating in the market etc., and a rating is defined for each customer based on a combination of the variables. This credit risk rating ranges from "AA" (the lowest risk) to "E" (the highest risk) (Note 7).

The balances of trade accounts receivable are classified as shown in the table below.

|    | Parent company |                | Consolidated   |                |
|----|----------------|----------------|----------------|----------------|
|    | 03/31/26       | 12/31/25       | 03/31/26       | 12/31/25       |
| AA | 110,597        | 143,674        | 111,204        | 146,967        |
| A  | 131,321        | 179,607        | 137,845        | 198,984        |
| B  | 16,662         | 22,464         | 17,437         | 23,356         |
| C  | 11,814         | 14,630         | 21,761         | 23,093         |
| D  | 18,835         | 20,631         | 29,997         | 39,439         |
| E  | 258            | 259            | 258            | 258            |
|    | <b>289,487</b> | <b>381,265</b> | <b>318,502</b> | <b>432,097</b> |

The Group has a Credit Committee that establishes guidelines and assesses and monitors the levels of credit risk that the Group is willing to accept in the course of its business.

In addition to the risk mitigating factors established in the credit policies, the Group has credit insurance to cover part of its sales.

The credit quality of financial assets not past due is assessed by reference to external credit ratings (if available) or to historical information about counterparty default rates.

#### c) Liquidity risk

The Group's Executive Board adopts a policy for managing its financial assets and liabilities, which is monitored by the Financial Department through operating strategies to ensure liquidity, profitability and security.

Cash flow forecasting is based on the approved budget and subsequent adjustments, which take into consideration, in addition to all the operating plans, the plan for raising funds to support planned investments, and the maturity schedule of the debts. The treasury department monitors daily the forecasts included in the cash flow projections to ensure sufficient cash for the Group to meet its operational needs. Additionally, the Group has previously approved the use of credit facilities available to increase and strengthen its liquidity position.

Cash and cash equivalents are primarily invested in highly liquid Repurchase Agreements and CDBs.

The Group maintains its leverage ratio so that it does not jeopardize its payment capacity and investments.





The table below breaks down financial liabilities into relevant maturity buckets, based on the remaining quarter between the balance sheet date and the contractual maturity date.

The amounts disclosed in the table are the contractual undiscounted cash flows.

|                                       | Parent company   |                      |                      |                  |
|---------------------------------------|------------------|----------------------|----------------------|------------------|
|                                       | Less than 1 year | Between 1 to 2 years | Between 2 to 5 years | Over 5 years old |
| <b>As of march 31, 2026:</b>          |                  |                      |                      |                  |
| Trade accounts payable                | 42,763           |                      |                      |                  |
| Dividends and interest on equity      | 52,799           |                      |                      |                  |
| Related parties                       | 118,107          |                      |                      |                  |
| Leases (i)                            | 6,634            | 2,088                |                      |                  |
| Other liabilities (ii)                | 26,533           | 14,958               |                      |                  |
|                                       | <b>246,836</b>   | <b>17,046</b>        | -                    | -                |
| <b>As of December 31, 2025:</b>       |                  |                      |                      |                  |
| Trade accounts payable                | 28,393           |                      |                      |                  |
| Dividends and interest on equity      | 52,799           |                      |                      |                  |
| Related parties                       | 139,245          |                      |                      |                  |
| Leases (i)                            | 6,912            | 1,957                |                      |                  |
| Other liabilities (ii)                | 30,785           | 15,070               |                      |                  |
|                                       | <b>258,134</b>   | <b>17,027</b>        | -                    | -                |
| <b>Consolidated</b>                   |                  |                      |                      |                  |
|                                       | Less than 1 year | Between 1 to 2 years | Between 2 to 5 years | Over 5 years old |
| <b>As of march 31, 2026:</b>          |                  |                      |                      |                  |
| Trade accounts payable                | 120,319          |                      |                      |                  |
| Loans and financing (i)               | 85,666           | 97,819               | 267,895              | 207,149          |
| Derivative financial instruments, net | 268              |                      |                      |                  |
| Dividends and interest on equity      | 52,799           |                      |                      |                  |
| Related parties                       | 6,542            |                      |                      |                  |
| Leases (i)                            | 9,377            | 7,633                |                      |                  |
| Other liabilities (ii)                | 72,658           | 35,711               |                      |                  |
|                                       | <b>347,629</b>   | <b>141,163</b>       | <b>267,895</b>       | <b>207,149</b>   |
| <b>As of December 31, 2025:</b>       |                  |                      |                      |                  |
| Trade accounts payable                | 97,332           |                      |                      |                  |
| Loans and financing (i)               | 80,030           | 83,980               | 233,777              | 197,845          |
| Derivative financial instruments, net | 597              |                      |                      |                  |
| Dividends and interest on equity      | 52,799           |                      |                      |                  |
| Related parties                       | 2,153            |                      |                      |                  |
| Leases (i)                            | 9,592            | 7,375                |                      |                  |
| Other liabilities (ii)                | 76,691           | 35,805               |                      |                  |
|                                       | <b>319,194</b>   | <b>127,160</b>       | <b>233,777</b>       | <b>197,845</b>   |

- (i) The amounts included in the table above are the contractual undiscounted cash flows, and therefore include future financial charges, and such amounts will not reconcile to the amounts disclosed for loans and financing in the balance sheet.
- (ii) Balances of salaries and social charges, taxes payable, income tax and social contribution payable, sales commissions and other short-term and long-term liabilities are considered.



**26.3 Capital management**

The Group's Executive Board objectives when managing capital are to safeguard its ability to continue as going concern in order to provide returns for the shareholders, as well as to maintain a strong credit rating in order to support business and maximize value for the shareholders.

The Group's Executive Board manages and adjusts its capital structure considering changes in the economic conditions. The capital structure arises from the selection between own (capital contributions and profit retention) and third-party capital to finance the operations. Capital is monitored on the basis of the financial leverage ratio, measured using indexes.

As of March 31, 2026 and December 31, 2025, the gearing ratios were as follows:

|                           | <b>Consolidated</b> |                  |
|---------------------------|---------------------|------------------|
|                           | <b>03/31/26</b>     | <b>12/31/25</b>  |
| Loans and financing       | 511,814             | 489,583          |
| Cash and cash equivalents | (401,103)           | (250,821)        |
| <b>Net debt</b>           | <b>110,711</b>      | <b>238,762</b>   |
| Equity                    | 816,491             | 796,857          |
| <b>Total capital</b>      | <b>927,202</b>      | <b>1,035,619</b> |
| <b>Leverage ratio %</b>   | <b>11.94</b>        | <b>23.06</b>     |

**27. Operational Segments (Consolidated)**

The Board of Directors is the chief decision-maker and has determined the following operating segments based on strategic business decisions: Such segments are as follows:

- Production animals – sale, in the domestic market, of veterinary drugs, vaccines and other products for cattle, pigs, poultry, sheep, horses and goats.
- Companion animals – sale, in the domestic market, of veterinary drugs and other products for dogs and cats.
- International operations - sale, in the foreign market, mainly to Latin American countries, of veterinary drugs, vaccines and other products for production and companion animals.

The products are manufactured at the Company's industrial facilities in the city of Cravinhos, State of São Paulo.

Sales are widely dispersed, and therefore, no individual customer accounts for more than 10% of net revenue.

Assets and liabilities, general and administrative expenses, research and innovation expenses, other income (expenses), net, finance income (costs), and income tax and social contribution are analyzed on an aggregate basis, and therefore are not presented by business segment.





The results by segment were as follows:

|  | 03/31/26           |                   |                          |                   |                 |
|--|--------------------|-------------------|--------------------------|-------------------|-----------------|
|  | Business segments  |                   |                          |                   |                 |
|  | Production animals | Companion animals | International operations | Unallocated costs | Total           |
| Revenues   | 176,455            | 45,115            | 28,899                   |                   | 250,469         |
| Cost of sales  | (93,637)           | (13,139)          | (8,751)                  |                   | (115,527)       |
| Gross profit   | 82,818             | 31,976            | 20,148                   |                   | 134,942         |
| Selling expenses                                       | (41,948)           | (10,202)          | (11,744)                 |                   | (63,894)        |
| <b>Results by segment</b>                              | <b>40,870</b>      | <b>21,774</b>     | <b>8,404</b>             |                   | <b>71,048</b>   |
| Expenses on research and innovation                    |                    |                   |                          | (18,429)          | (18,429)        |
| General and administrative expenses and other expenses |                    |                   |                          | (18,057)          | (18,057)        |
| Financial results                                      |                    |                   |                          | (1,332)           | (1,332)         |
| Income tax and social contribution                     |                    |                   |                          | (11,873)          | (11,873)        |
| <b>Unallocated results</b>                             |                    |                   |                          | <b>(49,691)</b>   | <b>(49,691)</b> |
| <b>Net income for the quarter</b>                      |                    |                   |                          |                   | <b>21,357</b>   |

|  | 03/31/25           |                   |                          |                   |                 |
|--|--------------------|-------------------|--------------------------|-------------------|-----------------|
|  | Business segments  |                   |                          |                   |                 |
|  | Production animals | Companion animals | International operations | Unallocated costs | Total           |
| Revenues   | 125,486            | 36,569            | 27,511                   |                   | 189,566         |
| Cost of sales  | (75,956)           | (11,896)          | (9,858)                  |                   | (97,710)        |
| Gross profit   | 49,530             | 24,673            | 17,653                   |                   | 91,856          |
| Selling expenses                                       | (35,800)           | (8,167)           | (9,282)                  |                   | (53,249)        |
| <b>Results by segment</b>                              | <b>13,730</b>      | <b>16,506</b>     | <b>8,371</b>             |                   | <b>38,607</b>   |
| Expenses on research and innovation                    |                    |                   |                          | (13,028)          | (13,028)        |
| General and administrative expenses and other expenses |                    |                   |                          | (17,007)          | (17,007)        |
| Financial results                                      |                    |                   |                          | (3,984)           | (3,984)         |
| Income tax and social contribution                     |                    |                   |                          | (2,540)           | (2,540)         |
| <b>Unallocated results</b>                             |                    |                   |                          | <b>(36,559)</b>   | <b>(36,559)</b> |
| <b>Net income for the quarter</b>                      |                    |                   |                          |                   | <b>2,048</b>    |

The breakdown, by country, of revenue from international operations is as follows:

|            | 03/31/26      | 03/31/25      |
|------------|---------------|---------------|
| Colombia   | 13,734        | 12,586        |
| Mexico     | 11,047        | 6,294         |
| Costa Rica | 942           | 2,841         |
| Panama     | 741           |               |
| Bolivia    | 610           |               |
| Peru       | 581           |               |
| Ecuador    | 468           |               |
| Guatemala  | 95            | 1,554         |
| Paraguay   |               | 3,922         |
| Others     | 681           | 314           |
|            | <b>28,899</b> | <b>27,511</b> |



**28. Subsequent events**

At the Annual and Extraordinary General Meeting held on April 16, 2026, the Company's shareholders approved the allocation of the consolidated net income for the year ended December 31, 2025, in the amount of R\$222,311, as follows: (i) allocation to the legal reserve of 5%, in the amount of R\$11,116; (ii) payment of the mandatory minimum dividends, equivalent to 25%, in the amount of R\$52,799, of which R\$50,000 were distributed as interest on equity, subject to withholding income tax (IRRF) of R\$6,474, resulting in a net amount of R\$43,526, and R\$9,273 were paid as mandatory dividends; and (iii) payment of supplementary dividends in the amount of R\$10,086.

Additionally, it should be noted that, in accordance with applicable legislation, dividends distributed from the 2026 fiscal year onward will be subject to withholding income tax (IRRF).

**29. Approval of the condensed interim individual e consolidated financial statements**

The condensed interim individual and consolidated financial statements were approved by the Board of Directors on May 5, 2026, and authorized for issuance.

\*\*\*

